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ABSTRACT 
THERAPEUTIC EFFICACY OF CERIUM OXIDE NANOPARTICLES AGAINST SEPSIS INDUCED 
MULTI-ORGAN DYSFUNCTION SYNDROME AND DEATH IN SPRAGUE DAWLEY RATS 
 
 Sepsis is a generalized term that signifies the presence of a pathogen in the blood 
stream to which the body responds by eliciting a systemic inflammatory response. Although 
sepsis is the leading cause of death in non-coronary intensive care units in United States, there 
are currently no FDA approved therapeutic drugs to treat this disorder. Cerium oxide 
nanoparticles (CeO2) have been shown to exhibit anti-oxidant, anti-inflammatory, and anti-
bacterial properties both in vitro and in vivo. Whether CeO2 nanoparticles can be used for the 
treatment of sepsis is currently unclear.  
 To investigate whether CeO2 nanoparticles can be used to treat moderate sepsis, twelve 
week old male Sprague Dawley rats were randomly divided into one of four different groups: 
control, CeO2 only, sepsis, and sepsis + CeO2. Moderate sepsis was induced by the 
intraperitoneal injection of cecal material (400mg/kg). The CeO2 nanoparticle treated animals 
received an intravenous injection of CeO2 nanoparticles (3.5mg/kg) at the time of sepsis 
induction. Treatment significantly decreased sepsis induced mortality. Treatment associated 
increases in animal survivability were associated with a significant decrease in serum IL-6, 
growth regulated alpha protein (KC/GRO), macrophage inflammatory protein-1 beta (MIP-1 β) 
macrophage derived chemokine (MDC), monocyte chemotactic protein-3 (MCP-3), myoglobin, 
macrophage inflammatory protein-3 beta (MIP-3β), eotaxin, leptin, macrophage inflammatory 
protein-2 (MIP-2), interferon gamma induced protein-10 (IP-10), tissue inhibitor of 
xvii 
 
metalloproteinases-1 (TIMP-1), plasminogen activator inhibitor-1 (PAI-1) and blood urea 
nitrogen (BUN).  
In an effort to further investigate whether there is a similar degree of response with 
smaller size and dose of CeO2 nanoparticles on the attenuation of severe sepsis, twelve week 
old male Sprague Dawley rats were randomly divided into one of four groups: control, CeO2 
only, sepsis and sepsis + CeO2. Severe sepsis was induced by the intraperitoneal injection of 
cecal material (600mg/kg). The CeO2 nanoparticle treated animals received an intravenous 
injection of CeO2 nanoparticles (0.5mg/kg) at the time of sepsis induction. Treatment with CeO2 
nanoparticles significantly decreased animal mortality and sepsis-induced hypothermia. 
Treatment associated increases in animal survivability were associated with evidence of 
diminished Erk 1/2 phosphorylation, Jak/Stat-3 activation, P-selectin levels and expression of 
vascular cell adhesion molecule-1 (VCAM-1) in the heart. Changes in cardiac signaling appeared 
to coincide with decreased serum IL-6, leukemia inhibitory factor, myoglobin and creatine 
kinase. In the liver, CeO2 nanoparticle treatment reduced sepsis-induced increases in hepatic 
superoxide levels, inducible nitric oxide synthase, and protein nitrosylation. Treatment 
associated increases in liver function were accompanied by diminished levels of serum reactive 
oxygen species (ROS) and several inflammatory markers. 
CeO2 nanoparticles were also found to attenuate sepsis-induced renal damage by 
preserving the renal brush border and attenuating the incidence of tubular dilatation. These 
changes in kidney morphology were accompanied by decreases in levels of serum β-2 
microglobulin, kidney injury molecule-1, cystatin-C, osteopontin, BUN, glucose, sodium, and 
potassium. At the cellular level, CeO2 nanoparticles attenuated the sepsis-induced activation of 
xviii 
 
Stat-3 and the cleavage of caspase-3. Taken together the data from this current study indicate 
that CeO2 nanoparticles can be used for the prevention of sepsis induced multi-organ 
dysfunction syndrome and death. Additional studies using other sepsis models or interventional 
time points may be warranted to determine the potential efficacy of using CeO2 nanoparticles 
to treat sepsis.  
 
 
Chapter 1  
Introduction 
 Sepsis is a pathological condition characterized by systemic inflammatory response 
syndrome (SIRS) that is triggered by host immune system as a countermeasure to an infectious 
agent in the blood [1]. Severe sepsis though curable when diagnosed early, can rapidly progress 
to a medical emergency, multi-organ dysfunction and death if not treated properly. Sepsis is 
not new. The term sepsis was first used by Hippocrates in the late 4th century BC to describe a 
process by which flesh rotted and lead to a foul smell [2]. In the late 1800’s Louis Pasteur 
discovered the link between microscopic organisms and infectious disease. Later on, Lister, 
Lennhartz, Asbough and others demonstrated that sepsis does not necessarily develop due to 
the presence of an infectious agent, but rather that it is the interaction between the host 
immune system and the agent that initiates the onset. As we have learned more about this 
disorder, the previously held notion of sepsis being primarily a disease of bacterial etiology has 
begun to expand to also incorporate the complex multi-factorial interaction of the host immune 
system.  
 Sepsis is the leading cause of death in non-coronary intensive care unit and ranks 
among the top ten mortality causing diseases in United States [3]. It is estimated that sepsis is 
responsible for ~60,000 deaths annually [4]. The costs for treating sepsis in 2008 alone were 
almost $15 billion and are expected to increase by >10% in each passing year [5].  Clearly new 
and better methods to treat this disorder are needed.  
 
Sepsis is the systemic reaction to an over-activated immune system 
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Sepsis usually arises as a secondary medical condition to an already existing localized 
infection of lungs, liver, kidney, or some other internal structure.  When the localized infection 
is left untreated, it can progress to the circulation and become systemic. A systemic infection 
occurs when the blood becomes contaminated with bacteria. Once this occurs, the immune 
system is set on high alert and may become over-activated which can result in the development 
of the systemic inflammatory response syndrome (SIRS). If not properly managed, SIRS can 
rapidly progress to sepsis, a state of multi-organ failure, sepsis shock and death. The molecular 
events which govern the transition from infection to SIRS, sepsis, and death are not yet 
understood although it is thought that the innate immune system may play a role.   
Upon invasion of the pathogens into the blood stream, host immune cells such as the 
circulating macrophages and neutrophils recognize the pathogen associated molecular patterns 
(PAMP’s) that are present on the cell surface which elicit the release of several inflammatory 
cytokines [6]. If this initial response overwhelms the invader, recovery usually ensues and there 
are no further problems. However, if the initial response is not sufficient, the immune system 
becomes further activated which can lead to the development of SIRS and sepsis.  
The inflammatory cascade is characterized by the early release of tumor necrosis factor 
–alpha and IL-1β that are thought to mediate the release of other pro-inflammatory cytokines 
including IL-6, IL-12, HMGB1 and prostaglandins [7]. In addition to these inflammatory 
mediators, the potent vasodilator nitric oxide is also released into circulation which can cause 
severe hypotension [8]. Decreases in pressure can lead to diminished blood flow velocity, which 
facilitates the interaction and binding of circulating macrophages and lymphocytes to 
endothelial selectins and extravasation into the extracellular matrix [9]. Increased extravasation 
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in turn, can lead to tissue edema and impaired tissue oxygenation, tissue hypoxia and organ 
dysfunction. 
The early and accurate diagnosis of sepsis is a goal that has yet to be met. Sepsis 
diagnosis is difficult due to the presence of several non-specific symptoms such as fever, rashes, 
anorexia and weakness that make it difficult to differentiate from diseases with similar 
symptoms until it is too late. The current first line treatment for sepsis is antibiotics but the 
effectiveness of these agents is often hindered by the presence of inflammatory cytokines. As 
such there is an immediate need for the development of new and better treatment modalities.  
Cerium oxide has a fluorite lattice structure with vacant electrons in its outermost 
orbital shells [10] which permits the cycling of ceria between its fully oxidized (Ce+4 ) and 
reduced (Ce+3) states [11]. Although cerium oxide is currently used in the manufacture of sun 
screens, polishing agents and as a fuel cell catalyst [12-14], recent studies have suggested that 
this molecule could also be utilized for biomedical applications.  For example,  studies have 
shown that CeO2 nanoparticles can protect cardiac progenitor cells from ROS induced oxidative 
stress [15] and normal human breast cells from radiation-induced apoptotic cell death invitro 
[16]. Similarly, others have shown that CeO2 nanoparticles can confer protection against carbon 
tetrachloride-induced oxidative stress in mice [17]. It has been also been shown that CeO2 
nanoparticles can act as an anti-bacterial agent by impairing the membrane integrity of E. coli 
[18, 19].  Whether CeO2 nanoparticles can help to prevent sepsis induced multi-organ 
dysfunction and death has to our knowledge, not been investigated.  
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Specific aims 
 Severe sepsis is characterized by a systemic inflammatory response that involves 
complex interactions between the host immune system and the pathological agent that usually 
results in a profound level of cellular damage to the host. Current treatment modalities are, 
unfortunately, not beneficial during the advanced stages of sepsis. Recent studies in vitro and in 
vivo have shown that CeO2 nanoparticles possess anti-bacterial, anti-inflammatory and anti-
oxidant properties [20-22]. Whether CeO2 nanoparticles can be used to prevent sepsis induced 
multi organ damage is not yet known. 
 The central focus of this current study is to determine whether CeO2 nanoparticles can 
attenuate sepsis induced organ damage and death in the laboratory rat. We hypothesize that 
CeO2 nanoparticle treatment will be associated with diminished sepsis-induced organ damage, 
which will result in improved animal survivability. This hypothesis will be tested by pursuing 
the following three specific aims:   
Specific Aim I: To determine whether CeO2 nanoparticles can attenuate the systemic 
inflammatory response syndrome during septic insult in male Sprague Dawley rats. 
Specific Aim II: To investigate if CeO2 nanoparticles can attenuate severe sepsis-induced 
inflammatory damage to the heart and liver during a septic insult in male Sprague Dawley 
rats. 
Specific Aim III: To determine whether CeO2 nanoparticles can attenuate severe sepsis-
induced inflammatory damage to the kidney during a septic insult in male Sprague Dawley 
rats.  
5 
Chapter 2  
2.1 Review of literature  
 A review of the pertinent literature concerning the present study will be 
presented in this chapter. The following areas will be addressed: 1. Etiology and epidemiology 
of sepsis, 2. Animal models of sepsis, 3. Pathophysiology of sepsis, and 4. Use of CeO2 
nanoparticles for biomedical application. 
 
2.2 Sepsis and systemic inflammatory response syndrome 
 Sepsis is characterized by a state of uncontrolled immune response to the presence of 
an infectious agent or their toxic metabolites [23]. Sepsis usually begins with the entry of 
pathogens or its toxins into the body. Upon entry, the host immune cells attempt to eliminate 
the infectious agent by direct ingestion and destruction or by the secretion of antibodies that 
bind to the pathogens making them targets to other host immune cells. During this process, the 
cells of immune system also release cytokines that act in autocrine or paracrine fashion to 
stimulate other cells. If the infection is not contained, cytokine release can proceed unabated 
giving rise to systemic inflammation or a systemic inflammatory response syndrome (SIRS) [24] 
(Figure 2-1). The diagnostic criteria for SIRS are: 
1. An increase in core body temperature above 38.0 °C or decrease in core body 
temperature below 36.0 °C. 
2. An increase in heart rate or tachycardia > 90 beats/minute. 
3. An increase in respiratory rate or tachypnea > 20 breaths/minute. 
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4. An increase in number of white blood cells (WBC) > 12x109 cells/L or decrease in WBC < 
4x109 cells/L. 
Although sepsis is characterized by SIRS, one should carefully evaluate the symptoms of 
disease as other pathological conditions including burns, cancer, pancreatitis can also give rise 
to the SIRS. As such, the important criterion for the diagnosis of sepsis is the documented 
presence of an infectious agent or its toxin.  
 
Figure 2-1. Progression of sepsis 
 
 
Source: https://my.vanderbilt.edu/sepsismonitor/progress-reports/ 
 
2.3 Etiology and epidemiology of sepsis 
Sepsis is a complex disease of multifactorial etiology that can result in death within a 
few hours to days depending on the immune status of the individual. Sepsis syndrome involves 
characteristics of several diseases including hemorrhagic/hypovolemic shock, and ischemia.  
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Although the occurrence of sepsis has been known for over 3000 years, the etiology and 
pathogenesis of sepsis is still not well understood [25].  
 Severe sepsis is one of the leading causes of death in United States and is the number 
one cause of death in non-intensive care coronary units [26].  According to a recent report from 
Center for Disease Control and Prevention, the incidence of sepsis has more than doubled over 
the last decade likely because of increase in aging population with chronic illness or greater 
increase in invasive surgical procedures, chemotherapy and immunosuppressive drugs. The 
costs for treating sepsis rose from almost $15 billion in 2008 to over $20 billion in 2011 making 
sepsis the most expensive disease to be billed to Medicare in 2011 [27]. Perhaps most telling, 
sepsis is thought to account for 60-80% of all deaths in developing countries, which is almost 6 
million deaths annually [28].  New and better methods to treat this disorder are clearly needed.  
 
2.4 Animal models of sepsis 
 Understanding the mechanism(s) of sepsis-induced MODS is of paramount importance 
to developing new therapeutic modalities. Unfortunately, the study of patients already in sepsis 
is oftentimes complicated by a lack of proper case history, the presence of existing comorbidity, 
and differences in septic stage. Moreover, people with sepsis are usually admitted to the 
hospital during the terminal stages of sepsis which can make it extremely difficult to tease out 
the mechanisms mediating sepsis progression. Given these and other ethical reasons, animals 
have been widely used to study this disorder. Although there are several animal models of 
sepsis currently in use, it should be noted that no one model adequately replicates the human 
condition. Animal models of sepsis include:  
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1. Lipopolysaccharide injection  
2. Injection of live bacteria  
3. Cecal ligation and puncture (CLP)  
4. Colon ascendens stent peritonitis (CASP)  
5. Polymicrobial sepsis model 
The injection of lipopolysaccharide (LPS) into animals to study the progression of sepsis 
and its underlying mechanisms was first documented in the early 1970’s with the isolation of 
endotoxin [29]. LPS is part of the outer membrane of gram-negative bacteria and is a primary 
cause of host toxicity. The LPS molecule (Figure 2-2) consists of three distinct subunits- a) 
outermost O-antigen b) a middle core region made of polysaccharide and c) an inner lipid A 
portion that is highly conserved and a key cause of bacterial toxicity [30]. While the use of LPS 
to understand the pathophysiology of sepsis has been vital to understanding SIRS, the LPS 
model as a whole does not fully model the sepsis seen in humans. First, LPS does not represent 
the whole bacteria and in addition, it does not explain why gram-positive bacteria, fungi, or 
viruses can also cause sepsis. Secondly, there is a vast difference in the degree of response to 
LPS between humans and animals. For example, studies have shown that the dosage of LPS in 
mice has to be, on average, two hundred and fifty fold higher to produce the same degree of 
cytokine response seen in humans [31]. Reasons for the discrepancy in the sensitivity to LPS to 
provide the same degree of immune response in humans and rodents might probably be 
attributed due to changes in balance of leukocyte subsets, NK inhibitory receptor families or 
the toll receptors [32]. Thirdly, the clinical course of sepsis progression in humans is much 
slower when compared with animal models [33].  
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Figure 2-2. Basic Structure of LPS 
 
Source: Doi:10.1038/nrmicro1068 
 
The injection of live bacteria into animals has paved the way for better understanding 
the mechanisms behind host-pathogen interactions. Experiments performed using different 
strains of bacteria, bacterial loads, loading types (bolus or slow and sustained release using 
infusion pumps), and routes of administration (intraperitoneal, intravenous or subcutaneous) 
where either one or several of these parameters were varied in different combinations have 
greatly added to our knowledge on progression of sepsis. Nonetheless, like the LPS model, this 
preparation has been widely criticized as it is thought that the injection of a single bacterial 
strain poorly mimics the polymicrobial infections seen in humans and secondly, because the 
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injected bacteria oftentimes fail to colonize the host as is seen with a natural infection. To 
overcome this barrier, studies employing polymicrobial agents have come into existence. 
 One of the first developed, and perhaps most common model of polymicrobial sepsis is 
the cecal ligation and puncture (CLP) procedure. The CLP model is currently regarded as the 
gold standard among all sepsis models [34]. This model involves ligation at ileocolic junction 
followed by a single or multiple punctures to the cecum to control the severity of sepsis (Figure 
2-3) [35]. This model of sepsis is highly favored among many investigators due to its ability to 
manifest the hemodynamic changes seen in clinical conditions [36]. In addition, this model is 
also thought to mimic the clinical presentation seen with abdominal trauma injuries. 
Nonetheless, one major downfall of this model is a lack of repeatability within and between 
different laboratories. 
 
Figure 2-3. Model of cecal ligation and puncture 
 
Source: DOI: 10.1016/j.ddmod.2011.10.002 
 
 A newer variation of the CLP model which is the colon ascendens stent peritonitis 
(CASP) (Figure 2-4) model of sepsis was developed by Zantl and collagues [37]. In this 
procedure, a stent is placed into the ascending colon which allows the passage of cecal 
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contents into the peritoneal cavity. One significant advantage of the CASP model over the CLP 
procedure is that this model is more rapid in eliciting an early and Toll like receptor -4 (TLR4) 
driven immune response than one that is driven by TNF-α. Whether this newly developed 
model will someday replace the older, and much more variable, CLP procedure as the model of 
choice for sepsis research is still unknown.  
  
Figure 2-4. Model of colon ascendens stent peritonitis 
 
Source: DOI: 10.1016/j.ddmod.2011.10.002 
 
 The third model of polymicrobial sepsis, and perhaps the newest of all, is the cecal 
inoculum procedure in which the cecal contents from a healthy donor animal are injected into 
three or more other animals to induce the sepsis response [38]. A major advantage over the LPS 
model is that this procedure uses a mixture of both gram positive and negative whole bacteria 
instead of just the LPS molecule. In contrast with CLP and CASP, the degree of variability is 
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minimized among animals as the amount of cecal material is fixed. Nonetheless, like all models, 
disadvantages also exist with the cecal inoculum procedure. In particular, the bolus injection of 
cecal contents creates a rapid immune response which differs from the presentation typically 
seen in clinical cases. 
  
2.5 Pathophysiology of sepsis 
The pathophysiology of sepsis is a very complex process that begins with the entry of 
the infectious agent into the body and its subsequent interaction with the host immune system 
which results in release of inflammatory mediators. Overt stimulation of immune system results 
in the excessive production of inflammatory mediators which include the cytokines, 
chemokines, prostaglandins and other vasoactive substances. This initial response, if excessive, 
can result in the systemic inflammatory response.  
Activation of the immune system begins with the binding of LPS to the 
lipopolysaccharide binding protein (LPS-BP) [39] which then binds to CD14, a 
glycosylphosphatidylinositol-anchored protein [40] that helps in recognition of the LPS by TLR4-
MD2 complex [41]. Upon recognition of LPS, the TLR4 undergoes oligomerization to propagate 
intracellular signaling via its adaptor proteins [42]. Downstream signaling is broadly divided into 
either MyD88 dependent (TIRAP pathway) or MyD88 independent (TRAM pathway) pathways 
(Figure 2-5). Upon stimulation of TLR4 by LPS, the Myd88 becomes activated and recruits IL-1 
receptor-associated kinase-4 (IRAK-4) [43]. IRAK-4 then activates its downstream protein TRAF6 
which forms a complex with ubiquitin conjugating enzymes and the subsequent activation of 
TAK1. It is thought that TAK1 is responsible for the phosphorylation and activation of 
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downstream IKK and MAPK proteins [44]. The activation of IKK leads to phosphorylation of IKB 
alpha that removes the inhibitory effect on nuclear transcription factor NF-kB [45] which allows 
it to translocate to the nucleus and cause the transcription of inflammatory cytokines [46]. 
 The MyD88 independent pathway [47] involves the activation of TRAM via the TLR4-LPS 
complex and the recruitment of downstream TRAF3 to IRF3. This recruitment is necessary for 
late phase activation of NF-kB and MAPK proteins [48]. In addition, activation of IRF3 is also 
necessary for the production of interferons [49] which are important defense mechanism 
against both virus and bacteria [50]. 
 
Figure 2-5. Mechanism of LPS induced production of inflammatory mediators 
 
Source: http://dx.doi.org/10.1016/j.cyto.2008.01.006 
 
It is thought that inflammatory mediators released through the activation of 
macrophages, neutrophils and other immune cells act in a paracrine and autocrine fashion on 
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different cell types [51]. Cytokines can increase the generation of intracellular levels of ROS 
through activation of NADPH oxidase or cause the synthesis of nitric oxide through induction of 
iNOS gene expression [52-54]. Reactive oxygen species (ROS) can lead to impaired cell function 
by activating or inhibiting proteins that are involved in cell signaling along with formation of 
advanced glycation end products [55-57]. ROS can also cause peroxidation of lipids that affect 
the integrity of cellular membranes [58] while nitric oxide reacts with superoxide and causes 
formation of peroxynitrite [59] and protein nitrosylation [60]. In addition, nitric oxide can also 
cause vessel vasodilation, hypotension, and marked circulatory impairment [61]. Although the 
effects of ROS and inflammatory mediators are systemic, the degree of insult oftentimes varies 
by organ. 
 
2.6 Multi-organ dysfunction syndrome 
The liver produces C-reactive protein, ceruloplasmin, ferritin, haptoglobin and 
coagulation and complement factors as part of the acute inflammatory phase [62]. These 
proteins are involved in xenobiotic opsonization, the entrapment of bacteria in blood clots and 
the inhibition of iron uptake leading to inhibition of bacterial replication [63]. Also involved in 
this acute response are the liver Kupffer cells which are responsible for a large portion of the 
cytokines produced during sepsis and the phagocytosis of bacteria [64]. This cytokine release, if 
excessive, can lead to impairments in glucose metabolism [65], decreased cytochrome p450 
activity, and hepatic dysfunction [66]. Histologically, hepatic failure is characterized by 
increased infiltration of polymorphonuclear (PMN) cells, centrilobular necrosis, sinusoidal 
dilation, and hepatocyte congestion [67]. Coincident with these changes in tissue morphology, 
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biochemical changes include increased levels of glutathione S transferase (GST), lactate 
dehydrogenase (LDH), aspartate transaminase (AST) and alanine transaminase (ALT) [68].    
While the liver is heavily involved in marshalling the acute response, the brunt of the 
insult is most likely felt most by the kidney as it is highly susceptible to the hypoxia oftentimes 
seen after changes in circulatory volume or severe vasodilation [69].  Within the kidneys, the 
proximal tubules are more susceptible to sepsis induced hypoxic damage than the distal tubules 
which can rely on glycolysis to provide energy [70]. Progressive renal failure is associated with 
increased blood levels of blood urea nitrogen (BUN) and creatinine that can lead to systemic 
organ failure [71]. Sepsis induced renal damage is histologically characterized by the loss of 
tubular brush border, increased tubular dilatation and vacuolization. In some instances, renal 
tubules also show the presence of sloughed endothelial cells. These changes result in 
intratubular obstruction that can progress to complete renal failure [72]. 
Along with the renal system, the lungs also exhibit signs of inflammatory damage 
through increased accumulation of neutrophils and monocytes that results in acute respiratory 
distress syndrome (ARDS) [73]. ARDS is physiologically characterized by pulmonary edema, 
arterial hypoxia and impaired excretion of carbon dioxide [74]. Accumulated PMN secrete 
inflammatory cytokines and vasodilators that result in decreased velocity of blood flow and 
impairment of the vascular endothelial barrier through the disruption of adherens junction 
proteins such as VE-cadherin [75].  
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Figure 2-6. Mechanism of sepsis induced cardiac failure 
 
Source: DOI: 10.1097/01.CCM.0000266683.64081.02 
 
Finally, during the advanced stage of sepsis there are marked cardiovascular 
complications including myocardial depression, impaired left ventricular diastolic function, and 
reduced ejection fraction (Figure 2-6) [76-78]. The underlying causes of sepsis-induced cardiac 
failure are multifactorial in nature but are usually attributed to the following: Increased 
cytokines which cause myofibrillar destruction, high nitric oxide levels which result in systemic 
hypotension, peroxynitrite formation and myofibrillar protein damage, infiltration of 
monocytes, impaired oxygenation due to failure of the coronary circulation, and increased 
prostaglandins which adversely affect coronary endothelial function. Histologically, sepsis 
induced cardiac failure is typically characterized by contraction band necrosis and the presence 
of increased sarcolemmal rupture [79]. 
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Figure 2-7. Schematic representation of sepsis induced multi-organ dysfunction 
 
Source: DOI: 10.1097/01.CCM.0000282072.56245.91 
 
 
2.6 Current therapies for sepsis 
 The clinical progression of sepsis in humans is usually characterized by an early 
hyperdynamic phase that later transitions to a hypodynamic phase.  The hyperdynamic phase is 
characterized by increased body temperature, respiratory rate and hyperglycemia. Conversely, 
the hypodynamic phase is associated with decreased body temperature, hypoglycemia and 
marked hypotension. The 2013 Guidelines from the International Surviving Sepsis Campaign 
suggest the following treatment strategy [80]: 
1. Recognize sepsis 
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2. Administer broad spectrum antibiotics and obtain blood and serum for microbial 
culture and estimation of lactate levels. 
3. Maintain blood pressure by administration of isotonic crystalloid fluids and achieve a 
urine output of 0.5ml/kg/hr. 
4. Administer vasopressor such as norepinephrine if the patient has not responded to 
early fluid administration and if there is still a marked hypotension. 
5. Finally measure patient’s blood oxygen saturation and try to identify the causes behind 
its alteration and restore them to base values. 
As a supportive treatment, a mild sedation without neuromuscular block can be indicated. 
Similarly, the administration of insulin is advised if subsequent glucose readings measure above 
180mg/dl and hemodialysis for renal failure patients are suggested [80]. While all the 
therapeutic agents are geared towards minimizing the alterations in normal homeostasis, none 
of them actually addresses the underlying causes for sepsis induced mortality.  
 
2.7 Nanotechnology 
 Nanotechnology can be described as the manipulation of matter at atomic or molecular 
scale to enhance its physical and chemical properties [81]. The word nanotechnology was first 
coined by Dr. Norio Taniguchi to describe processes related to manufacture of semiconductors 
[82]. The physical, chemical, and electro-magnetic properties of different substances can often 
vary considerably at the nanoscale [83]. Researchers and industrialists are now exploiting these 
properties for the design and manufacture of new therapeutic agents [84]. It is currently 
estimated that more than 800 products that utilize nanoparticles are being manufactured by 
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different companies [85]. Nanomedicine is an emerging branch of nanotechnology that is 
concerned with the development of therapeutic drugs for diseases such as cancer, diabetes and 
infectious diseases [86]. The most important contribution of nanomedicine is the development 
of therapeutic drugs that have enhanced permeation and retention (EPR) effects which allow 
them to successfully treat tumors that are inaccessible to commercial therapeutic agents [87]. 
In addition, recent animal studies have shown that the drugs designed through nanotechnology 
can be used to treat atherosclerosis, prevent age-associated macular degeneration and 
promote wound healing (Table 2-1) [88-90].  
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Table 2-1. List of FDA approved nanomedicines 
 
Source: http://www.uspharmacist.com/content/s/197/c/33020/ 
 
Currently, several types and formulations of nanoparticles are being investigated to 
effectively treat several different pathological conditions.  Nanoparticles made of gold, silver 
platinum and cerium oxide have been used to treat breast cancer, viral infections, and diabetes 
[91-93]. Multifunctional nanoparticles with increased stability, biocompatibility, and high 
intracellular penetration that can deliver therapeutic drugs are being used in preclinical trials to 
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treat cancer [94], for gene therapy [95], and for new types of multimodal imaging [96] (Figure 
2-8). Generally, nanoparticles such as iron oxide nanoparticles coated with specific antibody are 
used for targeted therapeutic approach as well as for diagnostic purposes. 
Figure 2-8. Schematic image of a multifunctional nanoparticle 
 
Source: Doi:10.1016/j.tibtech.2008.04.005 
 
2.8 Cerium oxide nanoparticles and its prospective applications in medicine 
 Cerium oxide (CeO2) is a rare earth metal oxide with a fluorite lattice structure that can 
cycle between oxidized (Ce+4) and reduced (Ce+3) states due to vacancies in the outermost 
orbital shells (Figure 2-9) [17]. It is thought that the ratio of Ce+3/ Ce+4 determines the ability of 
the CeO2 nanoparticles to act in the oxidation or reduction of other substances. One of the 
main qualities that distinguishes CeO2 nanoparticles from other elements in the lanthanoid 
series is the presence of partially filled subshells with electrons in orbitals 4f and 5d, which 
makes it a potential tool for biomedical applications [97].  At the nanoscale, CeO2 nanoparticles 
have increased chemical reactivity due to increase in surface to volume ratio. CeO2 
nanoparticles are used in the manufacture of cosmetics, polishing agents, diesel fuel additives, 
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and fuel cells [98-100]. Investigation into the use of CeO2 nanoparticles for biomedical 
applications is just beginning.  
Recent data has suggested that CeO2 nanoparticles can inhibit the progression of 
ovarian cancer by inhibition of angiogenesis without cytotoxic effects on different organs. 
[101]. Arya and coworkers have shown that CeO2 nanoparticle treatment can attenuate cellular 
ROS levels and protect primary cortical cells from apoptosis by acting to stabilize mitochondrial 
membrane potential [102].  Estevez and colleagues have shown that CeO2 nanoparticles can 
protect the mouse hippocampus from ischemic damage through reduction in levels of 
superoxide and nitric oxide [103]. Similarly, other studies have shown that CeO2 nanoparticles 
protect rodents from hypoxia induced oxidative stress [104] and that they can also protect 
endothelial cells, cardiac progenitor cells and pancreatic islets against H2O2 induced oxidative 
damage [15, 93, 100]. 
 
 Figure 2-9. Structure of Cerium oxide (CeO2) 
 
Source: http://en.wikipedia.org/wiki/Cerium(IV)_oxide 
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 Interestingly, researchers have also exploited the use of CeO2 nanoparticles as a potent 
anti-infectious agent. Thill and coworkers were among the first to formulate the idea of using 
CeO2 nanoparticles as an anti- bacterial agent against E.coli. In this work, they demonstrated 
that the nanoparticles are positively charged at neutral pH which allows the particles to bind to 
the negatively charged bacterial wall and induce bacterial cytotoxicity [18]. Independent studies 
by other researchers have demonstrated similar findings for B.subtilis [105]. In addition to its 
use as an anti-bacterial agent, other work has shown that CeO2 nanoparticles protect L929 cells 
from the vesicular stomatitis virus by inhibiting its replication [106]. Whether CeO2 
nanoparticles can function as an anti-infectious agent in vivo is still unclear and awaits 
investigation.   
 
2.9 Summary 
Severe sepsis is a life threatening disease with high mortality rate. The symptoms of 
sepsis are oftentimes confused with signs of general fever or flu making diagnosis difficult and 
delaying the initiation of medical intervention. Current sepsis treatments have failed to 
decrease the mortality rate as they are directed towards eliminating the bacteria but not the 
inflammatory mediators generated through host-bacterial interaction. In vitro and in vivo 
studies have shown that CeO2 nanoparticles exhibit potent anti-inflammatory, anti-oxidant and 
anti-infectious properties [22, 107, 108]. Whether CeO2 nanoparticles can be used to treat 
sepsis and its associated complications in vivo is not known. 
 
 
24 
 
Chapter 3  
The current chapter is focused on the hypothesis of this study and is set as three different 
papers each corresponding to a specific aim as stated in chapter-1. 
Paper-1  
The following paper corresponds to specific aim-1 and deals with the hypothesis whether CeO2 
nanoparticles can attenuate the systemic inflammatory response syndrome during septic insult 
in male Sprague Dawley rats. 
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Therapeutic applications of cerium oxide nanoparticles in treatment of polymicrobial sepsis 
induced systemic inflammatory response syndrome and associated mortality 
 
Running title- Treatment of sepsis induced systemic inflammatory response syndrome with 
CeO2 nanoparticles. 
Key words- Sepsis, cerium oxide nanoparticles, systemic inflammatory response syndrome, 
interleukin-6 
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Abstract 
Sepsis is a disease of medical emergency that is characterized by severe oxidative stress 
and system inflammation which leads to multi-organ failure and subsequent death. Cerium 
oxide nanoparticles (CeO2) have been shown to exhibit anti-oxidant and anti-inflammatory 
properties. This study tested whether administration of CeO2 nanoparticles could be beneficial 
in the treatment of sepsis. Male Sprague-Dawley rats received a septic insult by intraperitoneal 
injection of cecal inoculation (400 mg/kg). A single dose of CeO2 nanoparticles (3.5mg/kg) or 
vehicle was administrated to rats immediately after cecal inoculation. Treatment of sepsis 
animals with CeO2 nanoparticle significantly increased the survival rate along with decrease in 
major inflammatory cytokine, interleukin-6. Treatment associated increases in animal survival 
were associated with decreased serum KC/GROα, MIP1β, MDC, MCP3β, MIP3, Eotaxin, TIMP1, 
myoglobin and blood urea nitrogen. Taken together, the findings of this preliminary study 
indicate CeO2 nanoparticles may be useful as a therapeutic agent for treatment of sepsis. 
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Background 
Sepsis is associated with multiple-organ failure and is the leading cause of death in 
critically ill patients [109].  Despite decades of clinical research, the incidence of sepsis and the 
number of deaths resulting from sepsis continue to rise [110]. Current sepsis treatments are 
largely supportive in nature and consist of antibiotics, NSAIDS, intravenous fluids, and 
mechanical ventilator support where warranted [111]. Sepsis is characterized by a systemic 
inflammatory state due to the overproduction of reactive-oxygen species (ROS) that appears to 
be mediated, at least in part, by the activation of monocytes and macrophages. Indeed, it is 
thought that macrophage derived nitric oxide (NO), tumor necrosis factor (TNF-α), interleukin 
(IL)-1β and IL-6 play a major role in both the innate and acquired immune responses to bacterial 
infection [112, 113].  
Given the potential damaging effects of increased ROS on cellular structure and function 
some have hypothesized that anti-oxidant drugs may be useful for the treatment of sepsis [114, 
115]. To date, most in vivo interventional studies examining the effects of anti-oxidant 
therapies have focused on the use of traditional pharmacological treatments [116, 117]. 
Although promising for certain applications, pharmacological intervention can be hindered due 
to poor  bio-distribution and the requirement of multiple daily dosing since each antioxidant 
molecule is typically capable of scavenging only one free radical [118]. In an effort to overcome 
these limitations, some researchers have begun investigations into the use of nanomaterials for 
biomedical applications. Among the different nanomaterials under development, the use of 
cerium oxide (CeO2) nanoparticles may be of particular interest. Cerium oxide is a rare earth 
element of the lanthanide series which is widely used as an agent for ultraviolet absorption, 
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oxygen sensing and automatic catalytic converters [119]. Cerium oxide appears to exhibit the 
ability to transition between the Ce3+ and Ce4+ oxidative states which results in an auto 
regenerative redox cycling [120]. Although biomedical applications still await analysis of 
biocompatibility, recent data has indicated that these particles possess potent anti-bacterial 
activity, anti-oxidant activity [18, 105], and cytoprotective properties [121-124]. 
Whether CeO2 nanoparticles can be used for the treatment of sepsis has, to our 
knowledge, not been investigated.  Therefore the purpose of this study was to investigate the 
effect of CeO2 nanoparticle treatment on sepsis induced systemic inflammatory response 
syndrome and associated mortality in a laboratory model of severe sepsis. Our findings suggest 
that treatment with CeO2 nanoparticles may provide therapeutic benefit for the management 
of polymicrobial sepsis. 
 
Methods 
 
Characterization of CeO2 nanoparticles 
NanoActive CeO2 (99.9% purity as determined by ICP-MS; Lot #06-0118) was purchased 
from NanoScale corporation (Manhattan, KS, USA). The stock suspensions were prepared in 
deionized water by sonication using a Vibra Cell Sonicator (Sonics & Materials, Inc) at 600 W for 
2 min at room temperature. 
The hydrodynamic size and size distribution of CeO2 nanoparticles were evaluated in 
deionized water using a Particle Size Analyzer (HORIBA, Model-LB-550) equipped with a He-Ne 
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laser (633nm) using back scattered light.  Experiments were performed utilizing triplicate runs 
performed on three different days with freshly prepared samples.  
Particles were imaged in their native state using a MultiMode-8, Atomic Force 
Microscope (Bruker, Ewing, NJ) in the tapping mode. Briefly, a few drops of CeO2 nanoparticles 
were placed on freshly pealed mica substrate and allowed to dry in a petri dish floating in 
sonicator water bath (VWR, 50D, Radnor, PA) for 30 min at 240 W. Images were recorded in 
topography mode. Width and height measurements of adsorbed nanoparticles were made 
using the microscope’s section analysis software.  
For scanning electron microscopy, the particles were filtered with a 0.2 micron 
nucleopore filter.  The filters were then trimmed and one quarter was placed on an aluminum 
stub with double-stick carbon tape.  The sample was then sputter coated with gold/palladium 
and viewed on a Hitachi S4800 field emission scanning electron microscope. For transmission 
electron microscopy, the particles were diluted in double distilled filtered water and a drop was 
placed on a formvar-coated copper grid to dry.  The sample was viewed on a JEOL 1220 
transmission electron microscope. 
 
Induction of polymicrobial sepsis  
Ninety two male Sprague-Dawley rats weighing 390-440 g were obtained from Hill Top 
laboratories. Rats were housed two per cage and maintained in accordance with the guidelines 
provided by the Marshall University Institutional Animal Care and Use Committee (IACUC), and 
The Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) in a 
12:12- h dark-light cycle at a temperature of 22 ± 2oC. Animals were provided food and water 
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ad libitum, and acclimatized for at least 14 days prior to experimentation. The polymicrobial 
sepsis procedure was performed as outlined previously [38]. Briefly, animals were randomly 
assigned to one of four groups: sham control, CeO2 nanoparticle only, sepsis, and sepsis + CeO2 
nanoparticle groups. After being anesthetized with ketamine HCL: xylazine (45 mg/kg / 5 mg/kg 
i.p.) , the mid ventral surface is cleanly shaved and disinfected with 70% ethyl alcohol and a 
small 0.5 cm vertical midline abdominal incision was made. Animals in the sepsis and sepsis + 
CeO2 group received an i.p. injection of cecal inoculum (400mg cecal material/kg @ 5ml/kg in 
5% dextrose water). The cecal inoculum was prepared by mixing cecal contents obtained from 
donor rats. Fresh inoculum was prepared each day. The animals in control and sepsis group 
received sterile 5% dextrose water @ 5ml/kg i.p. All incisions were closed with interrupted silk 
sutures (3-0), and the abdomen was gently massaged to distribute the injectate. After the 
surgical procedure, animals in sham control and sepsis groups received 100 µl of sterile distilled 
water while animals in CeO2 and sepsis+CeO2 groups received 3.5 mg/kg of CeO2 nanoparticles 
in 100µl of sterile distilled water via tail vein injection. All rats were given free access to food 
and water after recovery from anesthesia. Animal survival was assessed for 14 days.  
In other experiments, animals were randomly assigned to one of the four groups as 
detailed previously. At 6 or 24 h after study initiation, animals were humanely sacrificed under 
anesthesia and blood was collected by cardiac puncture. Serum was separated and used for 
measuring various serum protein markers. 
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Enzyme linked immunosorbant assay and multiplex immunoassay 
ELISA was performed to determine the levels of serum IL-6. The cytokine interleukin-6 
(IL-6) was analyzed in different groups using a reagent kit from BD Bioscience (Franklin Lakes, 
NJ, USA)  as outlined by the manufacturer. Multiplexed serum protein markers were analyzed 
group wise by sending pooled samples to Rules-Based Medicine (Austin, TX, USA) using Rodent 
MAP® version 3.0 antigen analysis with a Luminex 100 instrument, as described previously 
[125].  
 
Estimation of serum biochemical markers 
Serum biochemical parameters were analyzed using an Abaxis VetScan® analyzer 
(Abaxis, Union City, CA, USA). Briefly, 100ul of serum was loaded into each vetscan cartridge 
and analyzed for changes in levels of serum albumin, alkaline phosphatase (ALP), alanine 
transaminase (ALT), amylase, BUN, calcium, phosphorus, glucose, sodium, potassium, globulin 
and total protein across different groups. 
 
Statistical analysis 
Results are presented as mean ± standard error of mean. For significant differences in 
survival curves, log-rank test (Mantel-Cox) was performed using Prism 5.0 software (GraphPad 
Software, La Jolla, CA). One-way analysis of variance (ANOVA) was used for comparison among 
different groups followed by Student Newman Keuls post hoc test to determine statistical 
significance using Sigmaplot 12 statistical software (Systat software Inc, San Jose, CA). A p-value 
of < 0.05 was considered to be statistically significant. 
32 
 
Results 
 
CeO2 nanoparticle characterization  
The mean hydrodynamic diameter of the CeO2 nanoparticles as determined by dynamic 
light scattering (DLS) was 140 ± 52.9 nm (Figure 3-1, Panel A). AFM analysis indicated an 
agglomerate size of 37.75 ± 3.8 nm width and 1.38 ± 0.28 nm height respectively (Figure 3-1, 
Panel B). SEM and TEM analysis of CeO2 nanoparticles determined the size of individual CeO2 
nanoparticles to be approximately  between 20-40nm (Figure 3-1, Panels C, D). 
 
CeO2 nanoparticles increased animal survivability in septic animals  
Compared to control animals, the animals inoculated with the cecal material exhibited 
several signs of shock including diarrhea, piloerection, and little or no spontaneous movement. 
However, sepsis animals that are treated with CeO2 nanoparticles showed significant 
improvement as seen by their alertness along with greater frequency in consumption of food 
and water when compared to sepsis group alone. Furthermore treatment of the septic animals 
with CeO2 nanoparticles increased animal survivability from ~25% to ~85% (Figure3-2). 
 
CeO2 nanoparticles treatment decreased sepsis-induced systemic inflammation 
Compared to controls, sepsis animals had increased serum IL-6 levels at 6 and 24 h 
(P<0.05). CeO2 nanoparticle treatment decreased serum IL-6 levels at 6h by 66% when 
compared with sepsis group (P<0.05) (Figure 3-3, Panel A). Although not significant, CeO2 
nanoparticles also attenuated the sepsis induced increase in serum IL-6 at 24h.  Similarly when 
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compared to controls, sepsis animals showed higher levels of growth regulated alpha protein 
(KC/GRO), macrophage inflammatory protein-1 beta (MIP-1 β) macrophage derived chemokine 
(MDC), monocyte chemotactic protein-3 (MCP-3), myoglobin, macrophage inflammatory 
protein-3 beta (MIP-3β), eotaxin, leptin, macrophage inflammatory protein-2 (MIP-2), 
interferon gamma induced protein-10 (IP-10), tissue inhibitor of metalloproteinases-1 (TIMP-1) 
and plasminogen activator inhibitor-1 (PAI-1) at 6 and 24 h (Figure 4A, 4B). However, treatment 
with CeO2 nanoparticle diminished the levels of KC/GRO, MIP-1β, MDC, MCP-3, myoglobin MIP-
3β, eotaxin, leptin  MIP-2, IP-10, and TIMP-1 by 1 – 3 fold (Figure 3-4, Panels A-D). 
The levels of several other analytes including macrophage colony stimulating factor-1 
(M-CSF-1), monocyte chemotactic protein-1 (MCP-1), stem cell factor (SCF), vascular 
endothelial growth factor A (VEGF-A), IL-1α, IL-7, Il-11 and lymphotactin exhibited a trend 
towards being increased with sepsis and decreased by at least one fold with CeO2 nanoparticle 
treatment (Figure 3-4, Panels E, F).  
 
CeO2 nanoparticles attenuated sepsis induced alterations in serum biochemical parameters 
 Sepsis is characterized by alterations in serum biochemical parameters such as BUN, 
sodium, potassium and phosphorus. Treatment with CeO2 nanoparticles attenuated sepsis 
induced increase in blood urea nitrogen and changes in sodium levels (Table 3-1) (p < 0.05). 
Although not significant, CeO2 nanoparticle also attenuated sepsis induced changes in serum 
alkaline phosphatase, amylase, phosphorus and potassium (Table 3-1). 
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DISCUSSION 
Despite decades of intensive investigation and significant advances in medical 
technology, management of patient care and antimicrobial therapy, the overall mortality rate in 
severe sepsis still remains unacceptably high [126]. The primary finding of this study was the 
observation that a single injection of CeO2 nanoparticles, in the absence of antibiotic treatment, 
fluid resuscitation, or other pharmacological intervention, was associated with a ~80% increase 
in animal survivability in the cecal inoculum model of severe sepsis (Figure 3-2).  
Previous studies have shown that the immune response to microbial insult is 
characterized by release of large amounts of pro-inflammatory cytokines which lead to multiple 
organ failure [127]. It is thought that elevations in serum IL-6 levels are highly correlated with 
the survival of the septic patient [128, 129]. Similar to other reports using this model, our in vivo 
studies showed that sepsis was associated with increased serum IL-6 levels [130] and 
importantly, that our nanoparticle based treatment significantly attenuated these increases 
(Figure 3-3). In addition to IL-6, it is also known that MODS is caused by other cytokines and 
chemokines such as eotaxins, MCP-1, MCP-3, etc. [131]. Consistent with previous data 
demonstrating that CeO2 nanoparticles can function as an antioxidant [132], the CeO2 
nanoparticle treatment also appeared to attenuate the expression of the serum cytokine and 
chemokine markers KC/GRO, MIP-1β, MDC, MCP-3β, myoglobin, MIP-3β, eotaxin, IP-10, and 
leptin (Figure 3-4). Given that many of these cytokines, are derived from the liver Kupffer cells 
these data suggest that our nanoparticle intervention is also capable of affecting macrophage 
function.   
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Sepsis is known to cause acute kidney injury (AKI) in about half of the infected 
individuals and has a very poor prognosis in comparison with the patients without AKI [133]. 
Previous studies have shown that sepsis induced AKI is characterized by increased serum levels 
of BUN and creatinine [134]. These changes are also accompanied by decreased sodium and 
increased potassium levels [135]. Consistent with previous work, we found that blood urea 
nitrogen (BUN) levels began to increase from 6 to 24 h, which is suggestive of kidney 
dysfunction. However, treatment with cerium oxide nanoparticles attenuated the increase in 
BUN at 6 h significantly (Table 3-1) (p<0.05). Although not statistically significant, cerium oxide 
nanoparticles appeared to attenuate sepsis induced increases in BUN, sodium potassium and 
phosphorus at 24 h time point. Similarly cerium oxide nanoparticles appear to increase serum 
amylase and glucose levels that were attenuated by sepsis at 24 h (Table 3-1).  
 
Conclusion 
Sepsis is a state of severe whole body inflammation that rapidly progress to MODS 
unless treated in time. Current therapeutic regime is largely ineffective in treating patients with 
sepsis mainly due to the increasing antibiotic resistance along with the lack of a specific anti-
inflammatory drug that could attenuate SIRS.  The main finding of the study is that a single dose 
of cerium oxide nanoparticles attenuated sepsis induced mortality and SIRS along with serum 
biochemical parameters in the absence of any supportive treatment. Future studies aimed at 
the molecular mechanism of action of cerium oxide nanoparticles at the cellular level against 
septic insult are warranted. 
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Figures 
Figure 3-1. Characterization of CeO2 nanoparticles. 
CeO2 nanoparticles are characterized by A) DLS B) AFM C) SEM D) TEM 
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Figure 3-2. CeO2 nanoparticles attenuated sepsis induced mortality.  
(n=8/group). 
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Figure 3-3. CeO2 nanoparticles attenuated sepsis induced increase in serum IL-6.  
“*”Significantly different from control group, “$” significantly difference from CeO2 group and 
“#” significantly difference from sepsis group (p˂0.05). (n=6/group) 
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Figure 3-4. CeO2 nanoparticles prevented sepsis induced SIRS by attenuating serum 
inflammatory proteins. 
 (n=6/group). 
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Tables 
Table 3-1. CeO2 nanoparticles attenuated sepsis induced changes in serum biochemical parameters. 
“*”Significantly different from control group, “$” significantly difference from CeO2 group and “#” significantly difference from sepsis 
group (p˂0.05). (n=6/group). 
Analyte 
6 h  
Control 
6 h 
Ceo2 
6h 
 Sepsis 
6h 
Sepsis+Ceo2 
24 h 
Control 
24 h  
Ceo2 
24h  
Sepsis 
24h 
Sepsis+Ceo2 
ALB 4.08±0.06 4.16±0.11 3.78±0.12$ 3.86±0.04 3.46±0.05 3.33±0.11 2.80±0.08*$ 2.78±0.08*$ 
ALP 195.00±19.96 196.25±20.78 160.88±15.22 176.13±25.47 265.88±22.02 238.13±36.40 91.29±4.83*$ 113.44±6.05*$ 
ALT 77.63±6.83 66.13±4.85 54.38±2.52* 55.13±3.96* 86.00±15.34 76.00±6.12 69.14±6.14 82.88±11.45 
Amylase 920.25±30.64 874.50±17.90 1003.50±57.40 972.25±32.65 863.63±17.89 889.25±66.22 561.71±58.26*$ 790.56±108.41 
BUN 25.00±1.83 29.25±2.86 39.13±1.38*$ 32.13±1.13*# 17.88±0.90 18.88±2.89 71.43±13.40*$ 41.22±5.60*$ 
Ca+ 10.75±0.26 10.60±0.22 10.91±0.22 10.478±0.18 10.50±0.14 10.50±0.19 10.19±0.08 10.11±0.21 
Phos 11.41±0.79 10.70±0.58 13.86±0.73$ 11.78±0.89 9.89±0.26 9.35±0.21 10.77±0.87 9.41±0.40 
Glu 376.88±12.44 362.75±16.26 312.88±66.71 283.75±40.21 341.63±11.36 267.63±22.30 101.86±11.88*$ 116.67±6.08*$ 
Na+ 142.00±0.82 144.25±10.13 140.88±1.39 138.50±0.66$ 143.75±0.73 143.75±1.01 145.00±1.23 140.378±1.15# 
K+ 7.16±0.25 7.46±0.23 6.98±0.23 6.79±0.16 7.59±0.28 7.63±0.21 8.29±0.25 7.64±0.23 
Glob 1.35±0.05 1.44±0.07 1.50±0.06 1.43±0.05 1.80±0.06 2.00±0.09 2.39±0.07*$ 2.34±0.07*$ 
TP 5.41±0.04 5.60±0.09 5.26±0.08$ 5.30±0.06$ 5.28±0.05 5.31±0.08 5.19±0.13 5.13±0.09 
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Paper-2  
The following paper corresponds to specific aim-2 and deals with the hypothesis whether CeO2 
nanoparticles can attenuate severe sepsis-induced inflammatory damage to the heart and liver 
during a septic insult in male Sprague Dawley rats. 
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Therapeutic applications of anti-oxidant and anti-inflammatory properties of cerium oxide 
nanoparticles in treatment of polymicrobial sepsis induced multi-organ failure 
 
Running title- Treatment of sepsis induced multi-organ failure with CeO2 nanoparticles. 
Key words- Sepsis, cerium oxide nanoparticles, cardiac failure, oxidative stress, inflammation 
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Abstract 
Sepsis is a life threatening disease that is associated with high mortality. Existing 
treatments have failed to improve survivability in septic patients. The purpose of the present 
study is to evaluate whether cerium oxide nanoparticles (CeO2) can prevent sepsis-induced 
mortality by preventing cardiac and hepatic dysfunction in male Sprague Dawley rats. 
Administration of a single dose (0.5mg/kg) of CeO2 nanoparticles intravenously to septic rats 
significantly improved survival rates and functioned to restore core body temperature towards 
baseline. Treatment-induced increases in animal survivability were associated with reduced 
hepatic oxidative stress, diminished serum cytokines, and decreased serum chemokine levels. 
Changes in serum inflammatory markers with treatment were accompanied by decreased 
vascular leak along with reduced serum creatine kinase activity and myoglobin levels.  In the 
heart, treatment diminished ERK 1/2 MAPK- Stat-3 signaling and endothelial activation. Taken 
together these data suggest that CeO2 nanoparticles can be used as a novel therapeutic agent 
for treatment of polymicrobial sepsis. 
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Introduction 
 Severe sepsis is a medical emergency that is caused by an excessive systemic 
inflammatory response to bacteria, fungi, or other xenobiotic. Although easily managed if 
caught early, diagnosis is often difficult due to non-specific symptoms which can result in 
delayed treatment and the development of multiple organ failure, septic shock and death.  
Standard treatment protocols advocate the administration of antibiotics in conjunction with 
supportive therapy which is largely ineffective once sepsis has developed.  
 The cardiovascular failure that characterizes the latter stages of sepsis has been largely 
attributed to the development of systemic hypotension due to severe vasodilatation and the 
microvascular leak caused by the derangement of the endothelial barrier. As this stage 
progresses, a state of depressed myocardial contractility occurs that oftentimes leads to 
irreversible myocardial damage [136].  
It is thought that much of the tissue damage seen in sepsis is caused by elevations in 
tissue reactive oxygen species (ROS) and reactive nitrogen species (RNS) subsequent to the 
increased release of cytokines that are a defining characteristic of the systemic inflammatory 
response syndrome (SIRS). Recent data has suggested that the liver Kupffer cells are the 
primary producer of the cytokines observed during SIRS [137]. Whether strategies designed to 
quickly attenuate cytokine release by the Kupffer cells can diminish serum cytokine levels and 
improve animal survivability following a lethal septic insult has, to our knowledge, not been 
investigated.  
 Cerium is a lanthanide metal that can undergo redox cycling from Ce4+ (oxidized) to Ce3+ 
(reduced) states and is usually found in a complex with oxygen as CeO2. In nanoparticle form, 
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CeO2 has been shown to function as a superoxide dismutase (SOD) mimetic [138], as a 
preventive measure to combat hypoxia-induced oxidative stress [104], and to protect different 
cell types against hydrogen peroxide-induced apoptosis [93, 100]. The use of CeO2 
nanoparticles to prevent sepsis-induced cardiovascular dysfunction has, to our knowledge, not 
been investigated.  
 
Materials and Methods 
 
Characterization of CeO2 nanoparticles 
Cerium oxide nanoparticles were purchased from US Research Nanomaterials, Inc 
(Houston, TX). Dynamic light scattering (DLS) was performed to estimate the mean size of CeO2 
nanoparticles in suspension using LB-550 DLS particle size analyzer (Horiba Scientific, Edison, 
NJ). Naked particle size of the CeO2 nanoparticles was characterized by transmission electron 
microscopy using JEOL JEM-2010 transmission electron microscope (TEM). X-ray diffraction 
(XRD) was performed by Scintag XDS 2000 powder diffractometer. Scanning transmission 
electron microscopy (STEM) images were acquired by the Aberration Corrected Analytical 
Electron Microscope (TEM/STEM JEOL JEM-ARM200CF, Japan) operated at 200 keV.  Electron 
energy loss spectroscopy (EELS) data for CeO2 nanoparticles were collected by Gatan Enfina.  
 
Induction of polymicrobial sepsis and therapeutic intervention 
One hundred twenty eight male Sprague Dawley rats aged 10 weeks were purchased 
from Hill-Top laboratories and housed in two-per cage at 22 ± 2°C with a 12:12 light-dark cycle 
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for 2 weeks prior to experimentation. Animals were fed with standard rodent chow and had 
access to food and water ad libitum. All surgical procedures were performed in accordance with 
the guidelines provided by the Marshall University Institutional Animal Care and Use 
Committee (IACUC), and The Association for Assessment and Accreditation of Laboratory 
Animal Care (AAALAC). Briefly, animals were anesthetized under isoflurane and a small mid 
ventral incision of 0.5 cm was made. Sham controls and CeO2 only groups were injected with 
5ml/kg of 5% sterile dextrose solution intraperitoneally and the incision was closed with 3-0 silk 
sutures. For the sepsis and sepsis+CeO2 groups, animals received a cecal inoculum of 600mg/kg 
BW in 5ml/kg BW of 5% sterile dextrose solution intraperitoneally. Cecal material was obtained 
from healthy rats and the material from each donor was used to induce sepsis in 4-5 rats. Sham 
control and sepsis groups received 200 µl of sterile distilled water intravenously via tail vein 
while the CeO2 and sepsis+CeO2 groups received CeO2 nanoparticles (0.5mg/kg) in 200 µl of 
sterile distilled water intravenously. Rectal temperature was recorded at 0, 3, 6, 12, 18, 24, and 
48h after receiving the cecal inoculum. Animals were observed for mortality for a period of 14 
days.  
 
Sample collection and estimation of organ ceria content  
Whole blood was collected by cardiac puncture and centrifuged at 5,000 x g for 10 min 
to collect serum at 3h and 18h time points. Animals were sacrificed under isoflurane anesthesia 
and the heart and liver were excised and washed in Krebs–Ringer bicarbonate buffer (KRB) to 
remove any blood, blotted to remove excess moisture, snap frozen in liquid nitrogen, and 
stored at -80°C for further analysis. 
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 Frozen hearts and livers were sent to Elemental Analysis Inc. (Lexington, KY) for 
estimation of ceria content by induction coupled plasma-mass spectrometry (ICP-MS) as 
described elsewhere [125]. 
 
Estimation of immune cell number and serum markers of inflammation  
The number of white blood cells (WBC), neutrophils, monocytes and lymphocytes were 
estimated in whole blood and peritoneal fluid collected at 3h and 18h time points using an 
Abaxis VetScan HM2 hematology analyzer (Abaxis, Union city, CA). Peritoneal fluid was 
obtained only from sepsis and sepsis and sepsis + CeO2 groups. Total serum ROS/RNS was 
measured using OxiSelect™ in vitro ROS/RNS assay kit (Cell Biolabs, Inc., San Diego, CA) as 
outlined by the manufacturer. Creatine kinase activity was measured in serum using a creatine 
kinase fluorometric assay kit (Cayman Chemical Company, Ann Arbor, MI) as directed by the kit 
instructions.  
 Serum and peritoneal fluid  samples from each of the different groups (n=6/group) 
collected at 3h and 18h time points were pooled and sent to Myriad RBM (Austin, TX) for the 
analysis of serum growth factors, cytokines and markers of inflammation using rodent MAP® V. 
3.0. Pooled samples were run in triplicate for statistical analysis.  
 
Liver histology and superoxide levels 
 Liver tissue was sectioned (4µm) using Leica CM1950 cryostat onto poly-L-lysine coated 
slides. Visualization of hematoxylin and eosin staining was performed to evaluate liver 
morphology using Evos XL microscope (Life technologies, Grand Island, NY). 
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 Levels of hepatic superoxide were estimated using dihydroethidium stain (Life 
technologies, Grand Island, NY). Briefly, liver sections were washed with PBS for 5 min and 
stained with 5µM solution of dihydroethidium for 1h at room temperature in the dark. Tissue 
sections were imaged using Evos FL microscope (Life technologies, Grand Island, NY) after PBS 
washing (3 x 5 min) and the levels of superoxide were estimated by image analysis using image 
J analysis software. 
 
SDS-PAGE and immunoblotting 
Approximately 100 mg of frozen tissue was taken and pulverized in liquid nitrogen and 
added to 900ul of T-PER (Pierce, Rockford, IL, USA) containing 1% protease and phosphatase 
inhibitors (P8340 and P5726, Sigma- Aldrich, St. Louis, MO, USA). Samples were homogenized 
and centrifuged at 13,000 rpm for 10 min at 4°C to collect the supernatant. Amount of protein 
in the samples was estimated through 660 nm assay (Pierce, Rockford, IL, USA) and normalized 
with T-PER and 4x Laemlli buffer to a final equal concentration across all samples. Equal amount 
of protein was loaded in 10% PAGEr Gold Precast gel (Lonza, Rockland, ME) and transferred to 
nitrocellulose membranes using standard protocol as detailed elsewhere [139]. Membranes 
were block with 5% milk in TBST for 1h at room temperature, washed thrice with TBST and 
probed for detection of ERK 1/2 MAPK , p-ERK 1/2 MAPK (Thr202/Tyr204), Stat-3, p-Stat-3 
(Tyr705), GAPDH (Cell Signaling Technology, Danvers, MA), P-selectin, VCAM-1, nitrotyrosine 
(Abcam, Cambridge, MA) and iNOS (Santa Cruz, Dallas, TX). Membranes were incubated with 
primary antibody overnight at 4°C, washed with TBST (3 x 5 min), and incubated with  
secondary anti-rabbit (Cell Signaling Technology, Danvers, MA) or anti-mouse antibody (Santa 
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Cruz, Dallas, TX) for 1 h at room temperature. Immunoreactive signal was visualized using 
Supersignal West Pico Chemiluminiscent substrate (Pierce, Rockford, IL, USA) and quantified 
using Fluorchem 9900 software (Protein Simple, Santa Clara, CA). Protein expression was 
normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH). 
 
Statistical analysis 
Results are presented as mean ± SEM. The log-rank test (Mantel-Cox) was performed 
using Prism 5.0 software (GraphPad Software, La Jolla, CA) to determine differences in animal 
survivability between groups. A two way analysis of variance using Tukey’s multiple comparison 
was performed where appropriate to evaluate differences in core temperature amongst the 
different groups. Differences in groups with equal sample size were evaluated by  one way 
analysis of variance using Student Newman Keuls or Dunn’s post hoc analysis for samples with 
unequal size. A one way ANOVA by ranks with Kruskal Wallis post hoc analysis was used for 
samples with non-normal distribution and a simple t-test was performed where appropriate 
using Sigmaplot 12 statistical software (Systat software Inc., San Jose, CA)  to test for the 
presence of significant differences between groups. A probability value of P < 0.05 was 
considered to be statistically significant. 
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Results 
 
Characterization of CeO2 nanoparticles 
The mean hydrodynamic diameter of CeO2 nanoparticles as estimated through dynamic 
light scattering experiments was found to be approximately 90nm (Figure 3-5, Panel A). TEM 
and STEM –HAAF analysis determined the size of individual nanoparticles to be approximately 
between 10-30nm (Figure 3-5, Panels B, C). The high resolution image of the CeO2 nanoparticle 
shows that the atoms of CeO2 are highly ordered (Figure 3-5, Panel D) and the EELS data (Figure 
3-5, Panel F) confirms the existence of the Ce and O element.  XRD was used to demonstrate 
cubic fluorite structure of CeO2 nanoparticles as seen through typical peaks (Figure 3-5, Panel 
G). 
 
Effect of CeO2 nanoparticles on sepsis induced mortality and hypothermia 
 Nanoparticle treatment decreased sepsis mortality from 100% to ~25% (Figure 3-
6, Panel A, P < 0.05).  Improvement in survivability was associated with a significant 
improvement in core body temperature from 18h (Figure 3-6, Panel B, P < 0.05).  
 
Nanoparticle treatment increased liver ceria and decreases systemic oxidative stress 
Compared to untreated animals, liver ceria content was increased in the animals 
receiving nanoparticle injections (Table 3-2). Nanoparticle treatment decreased sepsis-induced 
increases in total serum ROS levels (Figure 3-6, Panel C, P < 0.05).  
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Nanoparticle treatment decreased sepsis induced hepatic damage, tissue ROS and iNOS levels 
 Histological analysis of the livers obtained from control animals revealed normal hepatic 
and sinusoidal morphology. Nanoparticle treatment diminished sepsis-induced sinusoidal 
dilatation and hepatocyte congestion (Figure 3-7, Panels A-D). Consistent with the histological 
findings, tissue superoxide levels were increased with sepsis and decreased with nanoparticle 
treatment (Figure 3-7, Panels E-I, P < 0.05).  In a similar fashion, nanoparticle treatment also 
decreased sepsis induced increases in hepatic iNOS (Figure 3-8, Panel A, P<0.05) and protein 
nitrosylation at 3h (Figure 3-8, Panel B, P < 0.05).  
 
Nanoparticle treatment modulated sepsis related cytokines, chemokines and growth factors  
Nanoparticle treatment reversed sepsis-induced changes in several inflammatory 
chemokines (Table 3-3), cytokines (Table 3-4), and other inflammation related proteins (Table 
3-5, P < 0.05). Consistent with these data, nanoparticle treatment also decreased sepsis 
induced increases in the hepatic damage markers GST-α and GST-Mu (Table 3-5, P < 0.05).  
 
CeO2 nanoparticles reduced cardiac Jak-Stat and endothelial cell activation 
Sepsis increased and nanoparticle treatment decreased the phosphorylation of ERK 1/2 
(Figure 3-9, Panel A, P < 0.05) and Stat-3 (Figure 3-9, Panel C, P < 0.05). These changes in 
protein phosphorylation were accompanied by treatment associated decreases in P-selectin 
(Figure 3-9, Panel E, P < 0.05) and VCAM-1 in the septic animals at 3 and 18 h respectively 
(Figure 3-9, Panel F, P < 0.05). 
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Nanoparticle treatment decreased indices of sepsis induced cardiac muscle damage  
Sepsis increased and nanoparticle treatment decreased serum creatine kinase activity at 
18 h (Figure 3-10, Panel A, P < 0.05). Similarly, nanoparticle treatment decreased sepsis induced 
increases in circulating myoglobin levels at 3 h and 18 h (Table 3-5, P < 0.05). 
 
Cerium oxide nanoparticles modulated the inflammatory response in the peritoneum by 
decreasing the recruitment of immune cells 
 The number of circulating WBC, lymphocytes, monocytes and granulocytes was not 
changed with sepsis or nanoparticle treatment. Conversely, nanoparticle treatment reduced 
sepsis induced increases in the number of peritoneal lymphocytes and monocytes at 18 h 
(Table 3-6, P < 0.05). 
 
Discussion  
Despite decades of extensive research the sepsis induced mortality rate remains 
unacceptably high. The primary aim of this work was to evaluate whether CeO2 nanoparticles 
are protective against sepsis induced organ damage and death in the Sprague Dawley rat. To 
test this possibility, we utilized a polymicrobial model of severe sepsis that is characterized by 
100% mortality. Compared to the untreated controls, we found that a one-time CeO2 
nanoparticle intervention was able to decrease the mortality rate to only 25% (Figure 3-6). 
To explore the mechanistic basis of this finding, we determined where the injected CeO2 
nanoparticles may accumulate. Previous work has shown that injected CeO2 nanoparticles 
exhibit a proclivity to preferentially collect in the spleen, liver, kidneys, and lungs [17]. 
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Consistent with these data, we found significantly higher amounts of CeO2 nanoparticles in the 
liver compared to that observed in the heart (Table 3-2). To examine if the CeO2 nanoparticles 
were able to protect the liver against a septic insult, we next examined if treatment was 
associated with improvements in liver morphology. Our histological studies demonstrated that 
sepsis caused hepatic sinusoidal dilatation and congestion of hepatocytes which appeared to be 
decreased with CeO2 nanoparticle treatment (Figure 3-7). At the cellular level, sepsis is 
characterized by an increase in ROS and RNS which leads to cellular protein damage through 
carbonylation, nitrosylation or formation of AGE products [140-142].  Studies have shown that 
CeO2 nanoparticles act as a free radical scavenger in addition to accelerating the decay of 
peroxynitrite which can induce protein nitrosylation [22, 143, 144]. As expected from our 
morphological analysis, we found that sepsis increased hepatic superoxide production, systemic 
ROS levels, and iNOS expression and importantly, that these changes were attenuated with 
nanoparticle treatment (Figures 3-7, 3-8).  
Given that the liver is thought to be the primary source for the excessive inflammatory 
state seen with sepsis [145], we next sought to determine if the morphological changes we 
observed were also associated with modulation of the hepatic inflammatory response. 
Interestingly, we found that the CeO2 nanoparticle treatment attenuated sepsis induced 
alterations in several different types of chemokines, cytokines, growth factors and 
inflammatory proteins (Tables 3-3, 3-4, 3-5). Of particular importance, we found that the CeO2 
nanoparticle treatment functioned to attenuate sepsis-induced increases in serum GST-α and 
GST-mu which are characteristic of hepatic damage (Table 3-5). In addition, we also found that 
55 
 
the levels of the inflammatory cytokine IL-6 and LIF were also significantly decreased with 
treatment (Table 3-4). 
 Previous studies have shown that IL-6 and LIF can bind to gp130 to cause activation of 
the Jak-Stat pathway [146, 147]. Other work has shown that the phosphorylation of ERK 1/2 can 
lead to activation of Stat-3 that can cause increased transcription of several inflammatory 
mediators [148, 149]. Here we show that sepsis led to activation of Jak-Stat pathway in the 
failing heart. Treatment with CeO2 nanoparticles attenuated the activation of the ERK 1/2-Jak-
Stat pathway (Figure 3-9).  Moreover, studies have shown that Stat-3 signaling in the heart can 
cause increased microvascular permeability by increasing the expression of ICAM-1 and VCAM-
1 [150]. It is thought that the increased expression of ICAM-1 and VCAM-1 on the endothelium 
is one of the priming events for recruitment of macrophages and neutrophils into myocardium 
which can lead to increased microvascular permeability [151]. Consistent with our finding of 
decreased ERK 1/2-Jak-Stat activation, we found that nanoparticle treatment attenuated sepsis 
induced increases in VCAM-1 expression (Figure 3-9). To explore the possibility that this 
treatment induced decrease in endothelial activation was associated with diminished vascular 
leakiness, we next examined the effect of the nanoparticle intervention on the accumulation of 
inflammatory cells in the peritoneal cavity. As expected, we found that the treated animals 
exhibited decreases in the number of peritoneal monocytes and lymphocytes (Table 3-6). 
Finally, we next asked if treatment might decrease sepsis induced cardiac muscle damage. 
Creatine kinase and myoglobin have been used in various pre-clinical and clinical studies as 
markers of cardiac damage [152-156]. We found that the treated animals had less serum 
creatine kinase activity and myoglobin levels than the untreated septic animals (Figure 3-10, 
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Table 3-5).  While this study provides mechanistic insight into how the administration of CeO2 
nanoparticles might protect against a septic insult further experiments examining other organs 
and organ systems are likely warranted. 
 
Conclusion 
Our data suggest that a single dose of CeO2 nanoparticles in the absence of antibiotics or 
fluid resuscitation, or other supportive treatment can significantly decrease animal mortality in 
a severe sepsis model. This increase in animal survivability was associated with modulation of 
the hepatic inflammatory response (Figure 3-11).  
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Figures 
Figure 3-5. Characterization of CeO2 nanoparticles. 
CeO2 nanoparticles are characterized by A) DLS B) TEM C) STEM-HAAF D&E) STEM F) EELS G) 
XRD 
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Figure 3-6. Nanoparticle treatment decreased sepsis induced mortality, animal hypothermia 
and total serum ROS levels. 
A) Survival curve. B) Temperature. Control (n=8), CeO2 (n=8), Sepsis (n=16), Sepsis+CeO2 (n=16). 
*P<0.05 compared to control group, # P<0.05 compared to sepsis group and $ indicates that 
the last known temperature of dead sepsis animal has been used in consecutive time points for 
statistical purposes. C) Effect of nanoparticle treatment on total serum ROS levels (n=6/group).  
*P<0.05 compared to control group, $ P<0.05 compared to CeO2 group and # P<0.05 compared 
to sepsis group 
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Figure 3-7. Effect of CeO2 nanoparticles on sepsis induced hepatic inflammatory damage. 
H&E staining of 18h time point liver sections imaged at 200X magnification A) Control B) CeO2 
C) Sepsis D) Sepsis+CeO2. Dihydroethidium staining of 18h time point liver sections imaged at 
200X magnification E) Control F) CeO2 G) Sepsis H) Sepsis+CeO2 and I) Quantification of 
superoxide levels in different groups. *P<0.05 compared to control group, $ P<0.05 compared 
to CeO2 group and # P<0.05 compared to sepsis group. (n=4/group). 
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Figure 3-8. Effect of CeO2 nanoparticles on sepsis induced hepatic nitrosative stress. 
A) Levels of iNOS as determined by western blotting and normalized to GAPDH. B) Levels of 
nitrotyrosine as determined by western blotting and normalized to GAPDH. *P<0.05 compared 
to control group, $ P<0.05 compared to CeO2 group and # P<0.05 compared to sepsis group. 
(n=6/group). 
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Figure 3-9. Effect of CeO2 nanoparticles on sepsis induced cardiac inflammation. 
A & B) Levels of phosphorylated and total ERK1/2 as determined by western blotting and 
normalized to GAPDH respectively. C & D) Levels of phosphorylated and total Stat-3 as 
determined by western blotting and normalized to GAPDH respectively. E) Levels of P selectin 
as determined by western blotting and normalized to GAPDH F) Levels of VCAM-1 as 
determined by western blotting and normalized to GAPDH. *P<0.05 compared to control group, 
$ P<0.05 compared to CeO2 group and # P<0.05 compared to sepsis group. (n=6/group). 
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Figure 3-10. Cerium oxide nanoparticles attenuated sepsis induced serum creatine kinase 
activity. 
*P≤0.05 compared to control group, $ P≤0.05 compared to CeO2 group and # P≤0.05 compared 
to sepsis group. (n=6/group). 
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Figure 3-11. Schematic representation of mechanism of action of CeO2 nanoparticles against 
polymicrobial sepsis induced MODS and death. 
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  Tables 
Table 3-2. Levels of ceria content in heart and liver as determined through ICP-MS. 
Results are presented as mean ± SEM. N=3/group. 
 
Organ 
 
Control 
3h 
 
CeO2 3h 
 
Sepsis 
3h 
 
Sepsis + 
CeO2 3h 
 
Control 
18h 
 
Ceo2 18h 
 
Sepsis 
18h 
 
Sepsis + CeO2 
18h 
Heart <LLOQ <LLOQ <LLOQ <LLOQ <LLOQ <LLOQ <LLOQ <LLOQ 
Liver <LLOQ 
12.00±0.76 
ppm <LLOQ 
9.07±0.08 
ppm <LLOQ 
10.67±0.17 
ppm <LLOQ 
12.00±0.28 
ppm 
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Table 3-3. Effect of CeO2 nanoparticles on sepsis induced serum chemokines. 
*P<0.05 compared to control group, $ P<0.05 compared to CeO2 group and # P<0.05 compared 
to sepsis group. (n=6/group). 
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Analyte 
Serum Peritoneal fluid 
Sham control 
3h CeO2 3h Sepsis 3h Sepsis + CeO2 3h 
Sham control 
18h CeO2 18h Sepsis 18h 
Sepsis + CeO2 
18h Sepsis 18h 
Sepsis + CeO2 
18h 
Eotaxin (pg/mL) 362.33±1.76 354.67±8.29 
1273.33±28.48
*
$
 
856.00±14.47
*$#
 808.33±41.79 349.33±5.55
*
 
1866.67±26.03
*$
 
1020.00±5.77
*$#
 
2636.67±71.72 
3716.67±131.70
#
 
Growth-Regulated 
Alpha Protein 
(ng/mL) 
0.06±0.00 0.04±0.00
*
 3.50±0.06
*$
 2.57±0.03
*$#
 Below LLOQ Below LLOQ 5.23±0.07 2.20±0.06
#
 23.33±0.33 16.67±0.33
#
 
Macrophage-
Derived Chemokine  
(pg/mL) 
938.00±18.56 995.67±27.42 
1483.33±26.03
*
$
 
1553.33±31.80
*$
 1039.67±32.46 711.00±5.20
*
 
4410.00±55.68
*$
 
2500.00±60.0
0
*$#
 
24433.33±896.
91 
21633.33±1039.
76 
Macrophage 
Inflammatory 
Protein-1alpha 
(ng/mL) 
Below LLOQ Below LLOQ 4.20±0.20 6.37±0.17
#
 Below LLOQ Below LLOQ 20.67±0.67 6.70±0.29
#
 1740.00±17.32 1413.33±71.26
#
 
Macrophage 
Inflammatory 
Protein-1 beta 
(pg/mL) 
268.67±16.15 261.67±9.13 
3003.33±92.07
*
$
 
4766.67±93.87
*$
#
 
199.00±30.83 128.33±7.97 
8486.67±225.8
6
*$
 
5896.67±61.7
3
*$#
 
416000.00±13
576.94 
493666.67±252
08.02 
Macrophage 
Inflammatory 
Protein-2 (pg/mL) 
25.67±1.20 20.67±1.33
*
 318.33±7.26
*$
 215.00±2.65
*$#
 23.33±2.33 Below LLOQ 654.33±10.71
*
 
257.00±6.08
*
#
 
43933.33±276
0.64 
32533.33±1502.
59
#
 
Monocyte 
Chemotactic 
Protein 1 (pg/mL) 
897.33±16.50 848.00±17.95 
2270.00±65.06
*
$
 
2240.00±75.06
*$
 1483.33±42.56 973.00±19.66
*
 
2903.33±121.7
0
*$
 
2650.00±45.0
9
*$#
 
179333.33±66
6.67 
169000.00±929
1.57 
Monocyte 
Chemotactic 
Protein 3 (pg/mL) 
723.00±21.00 655.67±17.05 2016.67±6.67
*$
 
1700.00±30.55
*$
#
 
1009.00±23.97 597.67±12.55
*
 
3600.00±34.64
*$
 
3333.33±14.5
3
*$#
 
125333.33±31
79.80 
146000.00±568
6.24
#
 
Monocyte 
Chemotactic 
Protein-5 (pg/mL)  
Below LLOQ Below LLOQ 3.70±0.17 1.98±0.42
#
 Below LLOQ Below LLOQ Below LLOQ Below LLOQ Below LLOQ Below LLOQ 
T-Cell-Specific 
Protein RANTES 
(pg/mL) 
1.10±0.00 1.04±0.06 2.50±0.06
*$
 2.10±0.06
#
 1.43±0.03 0.74±0.01
*
 2.30±0.00
*$
 1.60±0.00
*$#
 4.37±0.03 3.20±0.12
#
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Table 3-4. Effect of CeO2 nanoparticles on sepsis induced serum cytokines. 
*P<0.05 compared to control group, $ P<0.05 compared to CeO2 group and # P<0.05 compared to sepsis group. (n=6/group). 
Analyte 
Serum Peritoneal fluid 
Sham 
control 3h CeO2 3h Sepsis 3h Sepsis + CeO2 3h 
Sham 
control 18h CeO2 18h Sepsis 18h 
Sepsis + CeO2 
18h Sepsis 18h Sepsis + CeO2 18h 
Interferon gamma 
(IFN-gamma) (pg/mL) 
Below LLOQ Below LLOQ 102.33±5.78 67.00±8.00
#
 36.67±9.21 Below LLOQ 46.67±14.33 38.33±9.74 48.67±2.19 15.67±0.67
#
 
Interferon gamma 
Induced Protein 10 (IP-
10) (pg/mL) 
42.33±2.60 40.67±2.85 192.33±4.98
*$
 153.33±5.55
*$#
 48.33±3.71 28.33±0.67
*
 117.00±1.73
*$
 91.67±2.67
*$#
 22.67±0.88 16.33±0.33
#
 
Interleukin-6 (IL-6) 
(pg/mL) 
Below LLOQ Below LLOQ 7.50±1.00 4.97±0.27 
Below 
LLOQ 
Below LLOQ 5.27±0.67 Below LLOQ 36.33±1.76 13.67±0.33
#
 
Interleukin-12 Subunit 
p70 (IL-12p70) (ng/mL) 
0.13±0.03 0.12±0.02 0.28±0.02
*$
 Below LLOQ 
Below 
LLOQ 
Below LLOQ Below LLOQ Below LLOQ 0.09±0.01 0.06±0.01
#
 
Leukemia Inhibitory 
Factor (LIF) (pg/mL) 
Below LLOQ Below LLOQ Below LLOQ Below LLOQ 
Below 
LLOQ 
Below LLOQ 1520.00±30.00 Below LLOQ 12000.00±321.46 7616.67±141.93
#
 
Oncostatin-M (OSM) 
(ng/mL) 
0.37±0.01 0.32±0.01
*
 0.81±0.05
*$
 0.66±0.03
*$#
 0.42±0.04 Below LLOQ 0.94±0.03
*
 0.73±0.02
*#
 19.33±1.76 27.67±1.33
#
 
Tumor Necrosis Factor 
alpha (TNF-alpha) 
(ng/mL) 
0.10±0.02 Below LLOQ 0.22±0.01
*
 0.13±0.01$
#
 
Below 
LLOQ 
Below LLOQ 0.14±0.01 0.14±0.01 0.39±0.01 0.34±0.01
#
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Table 3-5. Effect of CeO2 nanoparticles on sepsis induced serum growth factors and other proteins related to inflammation. 
*P<0.05 compared to control group, $ P<0.05 compared to CeO2 group and # P<0.05 compared to sepsis group. (n=6/group). 
Analyte 
Serum Peritoneal fluid 
Sham 
control 3h CeO2 3h Sepsis 3h 
Sepsis + CeO2 
3h 
Sham control 
18h CeO2 18h Sepsis 18h Sepsis + CeO2 18h Sepsis 18h Sepsis + CeO2 18h 
Fibroblast 
Growth Factor 
9 (ng/mL) 
3.82±1.27 3.87±0.38 10.20±0.42
*$
 7.60±0.26
*$#
 5.37±0.47 2.52±0.54
*
 11.67±0.33
*$
 9.43±0.38
*$#
 2.90±0.12 1.83±0.20
#
 
Leptin (ng/mL) 0.44±0.02 0.43±0.02 0.75±0.01
*$
 0.68±0.02
*$#
 0.27±0.01 0.25±0.01 2.97±0.15
*$
 1.83±0.07
#
 10.00±0.00 10.00±0.00 
Myeloperoxida
se  (ng/mL) 
11.00±0.58 11.33±0.33 30.67±0.88
*$
 
24.00±0.58
*$
#
 
25.67±0.33 25.00±0.58 39.33±0.67
*$
 34.00±0.00
*$#
 
16433.33±970.
11 11600.00±305.51
#
 
Myoglobin 
(ng/mL) 
1153.33±12.
02 
1373.33±31.
80
*
 
3083.33±23.33
*$
 
1546.67±20.2
8
*$#
 
1086.67±31.80 
1186.67±17.
64 
6220.00±200.75
*$
 
3246.67±52.39
*$#
 1004.33±22.41 756.67±15.45
#
 
Glutathione S-
Transferase 
alpha  (ng/mL) 
54.00±2.00 30.33±1.67* 69.33±2.19*$ 
42.67±3.93*$
# 
62.67±2.60 35.00±1.53* 
2126.67±56.67*
$ 
147.00±1.53*$# 213.33±11.78 138.00±6.56# 
Glutathione S-
Transferase Mu  
(ng/mL) 
376.33±20.2
0 
Below LLOQ 228.33±37.44* 
173.33±25.43
* 
232.00±0.00 Below LLOQ 
14133.33±328.3
0* 764.67±40.53
#
 
10666.67±272.
84 5830±245.02
#
 
Vascular 
Endothelial 
Growth Factor 
A (pg/mL) 
Below LLOQ Below LLOQ Below LLOQ Below LLOQ Below LLOQ Below LLOQ 459.00±12.70 296.67±31.33
#
 
5563.33±149.4
8 
5763.33±79.65 
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Table 3-6. Effect of CeO2 nanoparticles on sepsis induced changes in immune cells. 
$ P<0.05 compared to CeO2 group, # P<0.05 compared to sepsis group. (n=5-9/group). 
Cell Type 
Whole Blood Peritoneal Fluid 
Control 3h CeO2 3h Sepsis 3h 
Sepsis + 
CeO2 3h 
Control 18h CeO2 18h Sepsis 18h 
Sepsis + 
CeO2 18h 
Sepsis 18h 
Sepsis + CeO2 
18h 
WBC (10
9
/L) 2.156±0.689 1.410±0.331 1.406±0.235 2.158±0.652 2.821±0.385 2.124±0.330 2.106±0.439 2.612±0.486 27.045±2.357 24.506±6.031 
Lymphocytes 
(10
9
/L) 
0.946±0.321 0.887±0.362 0.646±0.094 1.292±0.356 1.194±0.253 0.959±0.245 1.266±0.314 1.514±0.335 3.191±0.441 1.756±0.382
#
 
Monocytes (10
9
/L) 0.060±0.0193 0.0117±0.003 0.120±0.031 0.092±0.055 0.126±0.041 0.191±0.034 0.0256±0.010
$
 0.191±0.075 2.766±0.385 1.440±0.513
#
 
Granulocytes 
(10
9
/L) 
1.153±0.418 0.540±0.159 0.640±0.148 0.778±0.314 1.504±0.349 0.973±0.090 0.025±0.09 0.910±0.142 21.091±1.981 19.124±4.318 
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Paper-3  
The following paper corresponds to specific aim-3 and deals with the hypothesis whether CeO2 
nanoparticles can attenuate severe sepsis-induced inflammatory damage to the kidney during a 
septic insult in male Sprague Dawley rats.  
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Cerium oxide nanoparticles attenuate polymicrobial sepsis induced acute kidney injury  
 
Running title- Treatment of sepsis induced AKI with cerium oxide nanoparticles 
 
Key Words- Cerium oxide nanoparticles, sepsis, kidney injury molecule-1, cystatin-C, oxidative 
stress 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
73 
 
Abstract 
 Sepsis is the leading cause of death in non-cardiac intensive care units. Sepsis-induced 
acute kidney injury (AKI) is a complicating morbidity that is associated with poor prognosis. 
Herein, we examined whether treatment with cerium oxide (CeO2) nanoparticles can reduce 
AKI in a severe polymicrobial sepsis model that causes severe microvascular leak that leads to 
deficit in circulatory volume and subsequent development of AKI. Administration of a single 
dose of CeO2 nanoparticles (0.5mg/kg) to male Sprague Dawley rats attenuated sepsis-induced 
tubular dilatation and the loss of brush border. These changes in renal structure were 
accompanied by decreases in sepsis-induced renal oxidative stress, stat-3 phosphorylation, and 
caspase-3 cleavage which are suggestive of diminished kidney inflammation and apoptosis. At 
the systemic level, CeO2 nanoparticle treatment reduced sepsis-induced increases in serum 
levels of kidney injury molecule-1 (KIM-1), cystatin-C, osteopontin, β-2 microglobulin, vascular 
endothelial growth factor-A (VEGF-A), blood urea nitrogen (BUN), potassium, sodium, and 
circulating glucose levels. Taken together, these data suggest that CeO2 nanoparticles may help 
to prevent the development of AKI during severe sepsis.  
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Introduction 
Severe sepsis is characterized by an overwhelming immune response that is often 
associated with acute kidney injury (AKI). Sepsis-induced AKI is thought to be primarily caused 
by the increased levels of reactive oxygen species (ROS) that are typically seen during the 
systemic inflammatory response syndrome (SIRS) that proceeds the development of frank 
sepsis [157, 158]. AKI is associated with damage to renal tubular cells, cellular apoptosis, 
increased tubular permeability, the loss of brush border [159] and increased tubular dilatation 
[72]. AKI is a serious complication which is associated with increased morbidity and poor 
prognosis [133]. Despite improvements in medical technology, current treatment modalities 
are largely supportive in nature and do little to address underlying causes.   
 Recent advances in nanotechnology have allowed the development of new compounds 
that can effectively scavenge ROS [160-162]. One such compound is cerium oxide (CeO2) which 
when formulated in nanoparticle form, may be useful for the treatment of inflammation [163], 
diabetes [93, 164], cancer [165, 166], and ischemic stroke [103]. Herein, we examined the 
therapeutic efficacy of using CeO2 nanoparticles for the treatment of sepsis-induced AKI.  On 
the basis of previous data demonstrating that CeO2 nanoparticles can function to scavenge ROS, 
we hypothesized that CeO2 nanoparticle treatment would be associated with decreased renal 
oxidative stress and sepsis-induced damage.  
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Materials and Methods 
 
Characterization of CeO2 nanoparticles 
 CeO2 nanoparticles were commercially purchased from US Research Nanomaterials, Inc. 
(Houston, TX). Atomic force microscopy was performed to estimate the mean particle size. 
Briefly, 20 μl of CeO2 nanoparticles was placed on freshly cleaved mica (V1 mica, SPI Inc, West 
Chester, PA) incubated for 15 minutes, rinsed with deionized water and dried under nitrogen. 
Nanoparticles were imaged in noncontact mode at a frequency of 319 kHz and a scan speed of 
0.5 Hz using a Nano-R microscope (Pacific Nanotechnology Inc., Santa Clara, CA) equipped with 
a TM300A noncontact probe (SensaProbes, Inc., Santa Clara, CA). The size of the CeO2 particles 
was characterized by a JEOL JEM-2010 transmission electron microscope. 
 
Polymicrobial sepsis induction and CeO2 nanoparticle treatment 
 Seventy two male Sprague Dawley rats aged 10 weeks were purchased from Hill-Top 
laboratories and allowed to acclimatize for 2 weeks prior to experimentation. All surgical 
procedures were performed in accordance with the guidelines provided by the Marshall 
University Institutional Animal Care and Use Committee (IACUC), and The Association for 
Assessment and Accreditation of Laboratory Animal Care (AAALAC). Briefly, animals were 
anesthetized under isoflurane and a small mid ventral incision of 0.5 cm was made. Sham 
controls and CeO2 only groups were injected with 5ml/kg of 5% sterile dextrose solution 
intraperitoneally (i.p.) while sepsis and sepsis+CeO2 groups  received cecal inoculum of 
600mg/kg BW in 5ml/kg BW of 5% sterile dextrose solution i.p. Cecal material was obtained 
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from healthy rats that served as donors. Sham control and sepsis groups were injected with 200 
µl of sterile distilled water intravenously (i.v.) while the CeO2 and sepsis+CeO2 groups received 
CeO2 nanoparticles (0.5mg/kg) in 200 µl of sterile distilled water i.v. via the tail vein at the time 
of sham surgery or sepsis induction.  
 
Tissue collection 
 Animals from different sets were humanely sacrificed under isoflurane anesthesia at 3h 
and 18h after sepsis induction and the kidneys were excised, the capsule removed and were 
washed in Krebs–Ringer bicarbonate buffer (KRB) to remove any blood. Kidneys were frozen in 
liquid nitrogen and stored at -80°C for further analysis. Serum was obtained from whole blood 
through cardiac puncture by centrifugation at 5,000 x g for 10 min at room temperature. 
 
Renal histology and staining for F-actin 
 Frozen kidneys were sectioned (4µm) with a Leica CM1950 cryostat and transferred to 
poly-L-lysine coated slides. Hematoxylin and eosin staining was performed using a Histoperfect 
kit (BBC biochemical, Seattle WA) to assess kidney morphology and imaged using an Evos XL 
microscope (Life Technologies, Grand Island, NY). Renal sections were also stained for F-actin 
using rhodamine phalloidin (Life Technologies, Grand Island, NY) as detailed elsewhere [167]. 
Briefly, frozen sections were washed with PBS and then fixed in 4% methanol free 
formaldehyde for 10 min. After a PBS wash (3 x 5 min), sections were permeabilized with 0.3% 
Triton X-100 in PBS for 20 min, washed with PBS (3 x 5 min) and then blocked with 1% BSA for 
30 min. Actin was stained by incubation of the tissue sections with 0.165 µM rhodamine 
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phalloidin for 20 min in the dark. After washing (3 x 5 min in PBS), tissues were mounted and 
imaged using an Evos FL microscope (Life Technologies, Grand Island, NY) before quantifying 
the fluorescence intensity using Image J analysis software. 
 
Estimation of renal superoxide levels 
 Levels of superoxide in renal sections were estimated using dihydroethidium staining 
[168]. Superoxide indicator dihydroethidium exhibits blue fluorescence under normal 
conditions, but exhibits a bright red fluorescence when oxidized and intercalates with DNA. 
Briefly, sections were washed with PBS and incubated with 5mM dihydroethidium for 1 h at 
room temperature in the dark. Sections were washed with PBS (3 x 5 min) and imaged with an 
Evos FL microscope (Life Technologies, Grand Island, NY). Mean fluorescence intensity was 
determined using Image J analysis software. 
 
SDS-PAGE and immunoblotting 
 Approximately 100 mg of frozen kidney was pulverized to a fine powder and then 
homogenized in 900ul of T-PER (Pierce, Rockford, IL, USA) containing protease and phosphatase 
inhibitors. Homogenates were centrifuged at 5,000 g x 10 min at 4°C to collect the supernatant. 
The 660nm protein assay (Pierce, Rockford, IL, USA) was used to determine the amount of 
protein in each sample. Samples were equally diluted with 4x Laemlli buffer, separated using 
SDS-PAGE on 10% PAGEr Gold Precast gels (Lonza, Rockland, ME) and then transferred to 
nitrocellulose membranes as detailed elsewhere [139]. Membranes were blocked with 5% milk 
in TBST for 1 h before being probed with antibodies against p-Stat-3 (Tyr 705), Stat-3, cleaved 
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caspase 3 and caspase 3 (Cell Signaling Technology, Danvers, MA). After washing (3 x 5 min 
TBST), membranes were incubated with secondary anti-rabbit antibody (Cell Signaling 
Technology, Danvers, MA). Immunoreactivity was visualized using Supersignal West Pico 
Chemiluminiscent substrate (Pierce, Rockford, IL, USA) before quantification using Fluorchem 
9900 software (Protein Simple, Santa Clara, CA). 
 
Multiplex immunoassay and serum biochemical analysis 
 Serum samples from different animals in each group were pooled and sent to Myriad 
RBM (Austin, TX) for the analysis of KIM-1, cystatin-C, osteopontin, β-2 microglobulin and VEGF-
A using rodent kidney multiplex immunoassay (MAP). Pooled samples were run in triplicate for 
statistical analysis. Levels of glucose, BUN, sodium and potassium were determined in serum 
using an Abaxis VetScan® analyzer (Abaxis, Union City, CA, USA). 
 
Statistical analysis 
 Results are presented in the form of mean ± standard error of mean. Differences 
between groups were determined using a one way analysis of variance (ANOVA) with Student 
Newman Keul’s post hoc analysis, an ANOVA on ranks with Student Newman Keul’s post hoc 
analysis for non-normally distributed samples or the Students t-test where applicable. A 
probability value of P < 0.05 was accepted as statistically significant. 
 
Results 
 
79 
 
Characterization of nanoceria 
 CeO2 nanoparticle size as determined using AFM was approximately 30 nm (Figure 3-12, 
Panel A). Analysis by scanning electron microscopy and transmission electron microscopy 
demonstrated a particle size of 10 – 40 nm (Figure 3-12, Panels B, C). Energy dispersive X-ray 
spectroscopy analysis of ceria and oxygen content was 80.4% and 16.36%, respectively (Figure 
3-12, Panel D). 
 
Nanoparticle treatment decreased serum indices of renal failure during sepsis  
 Compared to the control animals, sepsis increased the levels of β-2 microglobulin at 3 h 
and 18 h. Similarly, sepsis was also associated with increased levels of KIM-1, cystatin-C, 
osteopontin, and VEGF-A at 18h. CeO2 nanoparticle treatment attenuated sepsis-induced 
increases in KIM-1 cystatin-C, osteopontin, β-2 microglobulin, and VEGF-A at the 18 h time 
point (Table 3-7, P < 0.05). In a similar fashion, treatment also decreased sepsis-induced 
increases in blood glucose, BUN, and potassium (Table 3-8, P < 0.05).  
 
Cerium oxide nanoparticles attenuated sepsis induced renal damage and breakdown of 
tubular F-actin 
 Sepsis-induced AKI was characterized by renal tubular dilatation, a loss of the brush 
border and damage to the glomerular capillary network. These alterations in renal structure 
were attenuated with treatment (Figure 3-13, Panels A-H). In addition to changes in gross 
morphology, sepsis was also associated with a marked loss of F-actin in the proximal tubular 
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cells (Figure 3-14, Panel C) which was attenuated with nanoparticle treatment (Figure 3-14 
Panels D, E,  P < 0.05).  
 
Cerium oxide nanoparticles attenuated sepsis induced oxidative stress, prevented Stat-3 
activation and cleavage of caspase 3 
 Nanoparticle treatment decreased sepsis-induced increases in renal superoxide levels 
(Figure 3-15, P < 0.05), Stat-3 activation (Figure 3-16 Panel A, P < 0.05) and the cleavage of 
caspase-3 at 18h (Figure 3-16, Panel B, P < 0.05). 
 
Discussion 
 Although increases in serum levels of creatinine have been considered to be a 
traditional biomarker for AKI, recent data has suggested that sepsis-induced AKI may exhibit a 
distinct pathophysiology from that seen in non-septic AKI [169]. One of the distinguishing 
features between non-septic AKI vs septic AKI is the presence of non-hemodynamic 
mechanisms of cellular injury as result of immunological, toxic and inflammatory factors in 
sepsis. On the basis of these data, and others demonstrating that sepsis-associated decreases in 
creatinine production may limit the use of this molecule as a marker for AKI [170], we chose to 
examine how sepsis may affect the regulation of KIM-1, β-2 microglobulin, cystatin-C, and 
osteopontin. Kim-1 was chosen as it is thought to be a biomarker for proximal tubular injury 
[171] while β-2 microglobulin was selected as it has been shown to be a reliable indicator of 
marker for functional status of proximal tubular cells [172]. Similarly, we also chose to examine 
cystatin-C as it has been shown to be a reliable surrogate for the assessment of glomerular 
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filtration rate [173] while osteopontin is thought to be a marker of macrophage and neutrophil 
infiltration [174]. Consistent with our histopathological findings, we found that sepsis-induced 
increases in the levels of β-2 microglobulin, KIM-1, cystatin-C and osteopontin were attenuated 
with CeO2 nanoparticle treatment (Table 3-7). 
 In addition to changes in renal structure, sepsis has also been shown to affect the serum 
content of several renal metabolites and ions. Increases in blood urea nitrogen levels are a 
byproduct of protein metabolism with subsequent decrease in renal function. With sepsis, BUN 
levels have been shown to be increased due to decrease in circulatory volume as a result of 
marked vasodilation and microvascular leak. Consistent with this, we also found that sepsis 
increased serum BUN levels and importantly that these increases were diminished with 
nanoparticle treatment (Table 3-8). Similarly, sepsis has also been found to cause elevations in 
serum glucose levels [175]. Although not fully understood, it has been postulated that the 
development of hyperglycemia is associated with increased insulin clearance along with 
elevation in plasma levels of cortisol and glucagon that promote hepatic gluconeogenesis [176]. 
While elevation in glucose levels is an adaptive response to meet metabolic demands of the 
body such as wound healing, it is also shown that hyperglycemia causes predisposition to 
multiple complications such as neuropathy and MODS [177]. Supporting our analysis of serum 
BUN, we also found significant increases in serum glucose in the septic animals and that 
treatment appeared to attenuate the serum glucose levels. In addition to alterations in serum 
metabolites it is known that sepsis can also affect the concentration of serum Na+ / K+ ions. 
Indeed, hyponatremia and hyperkalemia are generally found in acute renal failure with 
decreased renal tubular flow rate [135]. Similar to previous studies we found that sepsis caused 
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a decrease in serum levels of sodium [178] and increase in potassium, which were attenuated 
with CeO2 nanoparticle treatment (Table 3-8). 
 Sepsis-induced AKI is characterized by increases in tissue ROS which are thought to be 
the cause of the renal inflammation, tubular dilatation, vacuolization, and loss of brush border 
that characterize this disorder [179, 180]. We observed similar findings in the present study and 
importantly, also found that CeO2 nanoparticle treatment appeared to attenuate these changes 
in the kidney. Specifically, we found that CeO2 nanoparticles attenuated sepsis induced loss of 
brush border in proximal tubular cells and also attenuated tubular dilatation. Moreover, 
treatment with CeO2 nanoparticles also improved renal glomerular integrity when compared to 
sepsis group (Figure 3-13). 
 To extend upon these findings, we next sought whether CeO2 nanoparticles can protect 
the kidney against sepsis-induced decreases in F-actin. AKI is characterized by loss of F-actin 
that leads to disruption in cytoskeleton network and impairs renal structural and functional 
integrity [167].  Consistent with our other assessments of renal function and morphology, we 
found that sepsis caused a significant decrease in loss of F-actin and importantly that 
nanoparticle treatment appeared to attenuate these changes (Figure 3-14). Taken together 
with our analysis of renal function, these data suggest that the CeO2 nanoparticle treatment 
functioned to improve both kidney structure and function.  
 We next sought to understand how the CeO2 nanoparticles may have prevented sepsis-
induced changes at the molecular level. Sepsis is characterized by increases in oxidative stress 
that result in uncontrolled SIRS and multi-organ failure [181]. Studies have shown that CeO2 
nanoparticles are potent ROS scavengers and that they can function as catalase and SOD 
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mimetics [17]. To investigate this possibility, we next examined how sepsis and nanoparticle 
treatment affected renal superoxide levels. Consistent with the effects of treatment on renal 
structure and function, we found that CeO2 nanoparticle administration significantly decreased 
sepsis-induced elevations in renal superoxide oxide levels (Figure 3-15). 
 Given the role that inflammation plays in the pathogenesis of sepsis, we next evaluated 
the Janus kinase signal transduction (Jak-Stat) pathway. The Jak-Stat pathway is one of the 
principal signaling mechanisms for a wide variety of cytokines and growth factors that are 
thought to be important in regulating the renal remodeling and fibrosis [182-185]. Consistent 
with these data, we found that sepsis was associated with the activation of Stat-3 in the kidney 
at 18hand importantly, that this activation was attenuated with nanoparticle treatment (Figure 
3-16). Whether this decrease in Stat-3 phosphorylation is due to treatment induced decreases 
in the amount of circulating cytokines or increased activation of intracellular phosphatases is 
currently unclear and will require further investigation.  
 In addition to inflammation, a growing body of evidence suggests that the  apoptosis of 
renal tubular cells is a major causes for AKI in sepsis [186]. Studies have shown that the 
activation of Jak-Stat pathway in renal tubular cells results in tubular cell death through caspase 
3 activation [183]. Other studies have shown that cleavage of caspase-3 is also responsible for 
the activation of gelsolin which has F-actin severing properties [187].  It is thought that the loss 
of F-actin is associated with cytoskeletal derangement that can lead to apoptotic cell death and 
development of AKI [167]. Supporting our F-actin data, we observed that sepsis was associated 
with evidence of increased caspase-3 cleavage at 18h. Similar to our other data, this finding 
appeared to be abrogated following nanoparticle treatment (Figure 3-16).  
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Conclusion 
 Taken together, the results of the current study demonstrate that a single dose of CeO2 
nanoparticles confers protection against severe sepsis induced acute kidney injury. Although 
not fully understood, our data suggest that the protective effect of the CeO2 nanoparticles 
appears to be related to their ability to scavenge reactive oxygen species which prevents 
caspase-3 mediated loss of F-actin and renal tubular cell damage. Further investigation to 
better understand the pharmacological potential of CeO2 nanoparticles for the treatment of 
sepsis induced AKI may be warranted. 
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Figures 
Figure 3-12. Characterization of CeO2 nanoparticles. 
CeO2 nanoparticles are characterized by A) AFM, B) SEM, C) TEM, D) EDS 
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Figure 3-13. CeO2 nanoparticles attenuated sepsis induced renal damage. 
Hematoxylin and eosin staining of 18h time point kidney sections A) Control B) CeO2 C) Sepsis D) 
Sepsis+CeO2 (imaged at 200X magnification) E) Control F) CeO2 G) Sepsis H) Sepsis+CeO2 
(imaged at 400X magnification) (n=4/group). 
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Figure 3-14. CeO2 nanoparticles attenuated sepsis induced loss of F-actin. 
Rhodamine phallodin staining for F-actin of 18h time point kidney sections imaged at 200X 
magnification A) Control B) CeO2 C) Sepsis D) Sepsis+CeO2 and E) Relative fluorescence intensity 
as a measure of F-actin. *P<0.05 compared to control group, $ P<0.05 compared to CeO2 group 
and # P<0.05 compared to sepsis group. (n=3/group). 
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Figure 3-15. CeO2 nanoparticles attenuated sepsis induced renal superoxide levels. 
Dihydroethidium staining of 18h time point kidney sections imaged at 200X magnification A) 
Control B) CeO2 C) Sepsis D) Sepsis+CeO2 and E) Quantification of superoxide levels in different 
groups. *P<0.05 compared to control group, $ P<0.05 compared to CeO2 group and # P<0.05 
compared to sepsis group. (n=4/group). 
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Figure 3-16. CeO2 nanoparticles attenuated sepsis induced renal inflammation and apoptosis. 
A) Levels of phosphorylated to total Stat-3 as determined by western blotting. B) Levels of 
cleaved to total caspase 3 as determined by western blotting. *P<0.05 compared to control 
group, $ P<0.05 compared to CeO2 group and # P<0.05 compared to sepsis group. (n=6/group). 
90 
 
Tables 
Table 3-7. CeO2 nanoparticles attenuated sepsis induced increases in biomarkers of AKI. 
*P<0.05 compared to control group, $ P<0.05 compared to CeO2 group and # P<0.05 compared to sepsis group. (n=6/group). 
Analyte 
Serum 
Sham 
control 3h 
CeO2 3h Sepsis 3h 
Sepsis + 
CeO2 3h 
Sham 
control 18h 
CeO2 18h Sepsis 18h 
Sepsis + CeO2 
18h 
Beta-2-
Microglobulin  
(µg/mL) 
54.0 ± 3.0 49.7 ± 2.4 76.0 ± 1.5*$ 77.3 ± 1.8*$ 52.0 ± 3.5 32.7 ± 1.5* 128.0 ± 5.9*$ 78.3 ± 7.2*$# 
Cystatin-C  
(ng/mL) 
578.7 ± 14.3 633.0 ±30.6 686.0 ± 14.5 690.3 ± 42.1 699.7 ± 52.7 555.3 ± 41.6 1890.0 ± 62.5*$ 1093.3 ± 37.6*$# 
KIM-1 
(ng/mL) 
Below LLOQ Below LLOQ Below LLOQ Below LLOQ Below LLOQ Below LLOQ 3.3 ±0.13 2.5 ± 0.1# 
Osteopontin 
(ng/mL) 
10.8 ± 1.2 11.0 ± 0.6 11.0 ± 0.6 12.3 ± 0.3 9.7 ± 0.0 7.9 ± 0.2* 72.3 ± 4.8*$ 36.3 ± 1.8*$# 
VEGF-A 
(pg/mL) 
Below LLOQ Below LLOQ Below LLOQ Below LLOQ Below LLOQ Below LLOQ 459.0 ± 12.7 296.7 ± 31.3# 
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Table 3-8. CeO2 nanoparticles attenuated sepsis induced alterations in serum biochemical parameters. 
*P<0.05 compared to control group, $ P<0.05 compared to CeO2 group and # P<0.05 compared to sepsis group. (n=6/group). 
Analyte 
Serum 
Sham 
control 3h CeO2 3h Sepsis 3h 
Sepsis + CeO2 
3h 
Sham 
control 18h CeO2 18h Sepsis 18h 
Sepsis + 
CeO2 18h 
Glucose 284.0 ± 8.1 262.3 ± 10.1 
426.9 ± 
19.7*$ 
308.6 ± 22.6# 245.3 ± 13.3 290.6 ± 17.3* 105.5 ± 8.5*$ 125.3 ± 5.1*$ 
Blood urea 
nitrogen 
22.0 ± 1.1 21.0 ± 1.0 29.9 ± 2.0*$ 24.71±1.17# 19.2 ± 0.5 18.5 ± 0.9 71.3 ± 7.2*$ 57.4 ± 3.1$ 
Sodium 142.4 ± 0.7 142.9 ± 0.9 136.8 ± 1.4*$ 140.1 ± 0.5# 142.0 ± 1.2 141.6 ± 0.9 138.8 ± 0.8 140.6 ± 0.5 
Potassium 5.9 ± 0.4 5.4 ± 0.1 6.4 ± 0.3 6.3 ± 0.2 5.6 ± 0.2 5.8 ± 0.3 7.8 ± 0.2*$ 7.1 ± 0.2*$# 
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Chapter 4  
Discussion 
 Sepsis is the leading cause of death globally in spite of intense research efforts and 
recent advance in medical care [188]. The complex pathophysiology of sepsis in conjunction 
with growing antibiotic resistance is likely to further worsen the prognosis of septic patients.  
Although not fully understood, it is thought that the uncontrolled systemic inflammatory 
response that characterizes the transition from sepsis to multiple organ dysfunction syndrome 
(MODS) is the primary  cause of septic associated death [181]. 
 Over the past decade, the field of nanotechnology has seen immense growth and it has 
played a vital role in the continued growth of several different manufacturing sectors [84, 189]. 
More recently, nanotechnology has also begun to be used for biomedical applications where 
the unique properties of nanomaterials can be exploited for diagnostic and even therapeutic 
uses [190, 191].  As an example, and of particular relevance to this research, CeO2 nanoparticles 
are currently being tested for the detection of lactate levels and chronic inflammation [192], 
the treatment of radiation-induced damage [193], ovarian cancer [166] and stroke [194].  
The main objective of the current study is to evaluate whether CeO2 nanoparticles can 
be used to prevent sepsis induced MODS and death. To accomplish this objective, this study 
was divided into two different sub-projects. In the first, we examined whether CeO2 
nanoparticles could be used to protect Sprague Dawley rats from moderate sepsis induced SIRS. 
Once completed, we then undertook the second aspect of this study where we examined if 
CeO2 nanoparticles could be used to prevent against severe sepsis induced MODS. Our findings 
are summarized as follows: 
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 Effect of CeO2 nanoparticles on sepsis induced hypothermia and mortality 
Sepsis is characterized by high mortality rates that are closely associated with decreased 
core body temperature [195]. Previous studies have shown that the sepsis-induced cytokine 
response is associated with increased levels of TNF-α, IL-1β and prostaglandins which function 
to alter the hypothalamic set point causing hypothermia [196]. Coincident with the release of 
cytokines, other work has shown that sepsis also causes the release of the potent vasodilator 
nitric oxide which can cause the loss of heat from the peripheral circulation [197]. In the current 
study, we found that the induction of moderate sepsis in male Sprague Dawley rats results in 
mortality rate of 75% while severe sepsis results in 100% mortality rate. We also observed that 
decreases in core body temperature in the severely septic animals were closely associated with 
the death of the animal. Treatment with the CeO2 nanoparticles reduced the mortality rate to 
~17% in animals with moderate sepsis and to 25% in animals with severe sepsis. Treatment 
induced increases in survivability were found to be associated with the restoration of core body 
temperature towards baseline. 
 
Effect of CeO2 nanoparticles on sepsis induced systemic inflammatory response 
It was previously thought that the sepsis induced mortality was a result of direct 
microbial insult. More recently, additional data has suggested that sepsis-induced mortality is 
more likely to be caused by the uncontrolled immune response that characterizes the 
development of MODS [198]. Similar to previous studies, we found that both moderate and 
severe sepsis resulted in increased levels of serum and peritoneal fluid inflammatory cytokines, 
chemokines and growth factors. These increases in systemic inflammation were attenuated 
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with CeO2 nanoparticle treatment. Consistent with these data, other work has also suggested 
that CeO2 nanoparticles can also modulate cellular ROS levels / inflammation [199]. How 
treatment with CeO2 nanoparticles might function to decrease cellular ROS levels / 
inflammation in vivo is currently unclear and will require further study.  
 
Effect of CeO2 nanoparticles on sepsis induced multi-organ dysfunction syndrome 
  Previous studies have shown that the sepsis-induced inflammatory cytokine storm leads 
to MODS and death [200]. It is thought that much of the circulating cytokines seen during the 
cytokine storm are released by the resident macrophages, Kuppfer cells, of the liver [201]. 
Similar to other studies, we found that the intravenous injection of CeO2 nanoparticles lead to 
their highest accumulation in liver but not in other organs [17]. We next sought to evaluate 
whether CeO2 nanoparticles can modulate oxidative and nitrosative stress. As expected, CeO2 
nanoparticles attenuated sepsis-induced hepatic superoxide levels along with protein 
nitrosylation. In addition, CeO2 nanoparticles also attenuated GST-α and GST-mu which are 
hallmarks of hepatic damage. We next examined whether CeO2 nanoparticles can prevent 
sepsis induced cardiac failure and found that CeO2 nanoparticles attenuated serum myoglobin 
levels and creatine kinase activity along with attenuation in cardiac ERK1/2-Jak-Stat pathway 
and decreased expression of VCAM-1.  In addition, we also found that CeO2 nanoparticles 
attenuated sepsis-induced increases in renal damage markers BUN, KIM-1, cystatin C, 
osteopontin and β-2 microglobulin. Histologically, CeO2 nanoparticles attenuated sepsis-
induced tubular dilatation, the loss of brush border, and improved F-actin levels in the kidney. 
These changes were associated with decrease in Stat-3 activation and cleavage of caspase 3. 
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Taken together, the data from the current study suggest that CeO2 nanoparticles protect 
against sepsis-induced organ damage by modulating the hepatic inflammatory response.  
Summary 
1. CeO2 nanoparticles significantly improve survivability in male Sprague Dawley rats 
against moderate and severe septic insults. 
2. Improvement in survival rate is associated with the restoration of core body 
temperature towards baseline. 
3. CeO2 nanoparticles specifically accumulate in the liver and modulate the hepatic 
inflammatory response to septic insult. 
4. CeO2 nanoparticles attenuate hepatic damage by decreasing sepsis-induced oxidative 
and nitrosative stress which is associated with improvements in hepatic morphology. 
Modulation of the hepatic inflammatory response by CeO2 nanoparticles is associated 
with decreased levels of systemic inflammatory mediators. 
5. CeO2 nanoparticles in conjunction with decreased cytokine release from the liver appear 
to protect the heart during sepsis by attenuating the activation of the inflammatory ERK 
1/2-Jak-Stat pathway. 
6. Nanoparticle treatment is associated with evidence of decreased sepsis-induced cardiac 
damage and microvascular leak. 
7.  CeO2 nanoparticles attenuate sepsis-induced alterations in serum myoglobin and 
creatine kinase activity levels. 
8. CeO2 nanoparticles attenuate sepsis-induced AKI by preserving the structural integrity 
and F-actin. 
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9. CeO2 nanoparticles attenuate sepsis-induced increases in renal oxidative stress and 
apoptosis by inhibition of Stat-3 and cleavage of caspase 3. 
 
Figure 4-1. Schematic representation of mechanism of action of CeO2 nanoparticles against 
severe sepsis induced MODS and death. 
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Future directions 
 The present study provides a first glimpse detailing the potential protective effects of 
CeO2 nanoparticles against sepsis induced MODS and death. While the study is novel, the 
limitation of the study is that we tested the effects of the co-administration of CeO2 
nanoparticles at the time of sepsis induction. It is unlikely that this situation models a real-
world clinical situation where sepsis is diagnosed prior to the initiation of treatment.   Similarly, 
the animals used in this study did not suffer from comorbidities which is often seen in clinical 
settings. To address these shortcomings, further studies based on the following specific aims 
may be warranted. 
Specific Aim I: 
 Severe sepsis is a complex pathophysiological process in which the host immune system 
becomes deregulated leading to organ failure. Early stages of systemic septic insult are 
characterized by the activation of circulating macrophages and neutrophils that cause the 
release of pro-inflammatory mediators such as TNF- α and  IL-1β [202]. These cytokines then 
activate the resident macrophages such as Kupffer cells in liver, mesangial cells in kidney and 
dust cells in lungs. Because the liver is the primary organ for the synthesis of acute phase 
proteins and it also contains the largest number of resident macrophages, it may be useful to 
determine whether CeO2 nanoparticles can prevent cytokine induced activation of Kupffer cells. 
While the current study found that CeO2 nanoparticles accumulate in the liver, it is still unclear 
whether CeO2 nanoparticles modulate Kupffer cell activation. To specifically address this 
question, Kupffer cells from livers of animals injected with CeO2 nanoparticles could be isolated 
and analyzed for the presence of ceria content through ICPMS and electron microscopy. Finally 
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to determine whether CeO2 nanoparticles can inhibit Kupffer cell activation, the determination 
of mRNA expression for various inflammatory cytokines in Kupffer cells across different groups 
may be warranted. 
Specific Aim II: 
 The sepsis mortality rate is higher in neonatal children and the elderly due to an 
underdeveloped or compromised immune system [203]. The current study was performed in 
adult male Sprague Dawley rats where their innate and adaptive immune system has 
completely developed.  Whether CeO2 nanoparticles are efficacious for the treatment of the 
very young or the aged has not been investigated.  
 Previous studies in conjunction with this current study have demonstrated that CeO2 
nanoparticles exhibit the ability to scavenger ROS [11]. Unlike traditional anti-oxidants or anti-
inflammatory agents that are rapidly metabolized and eliminated, CeO2 nanoparticles do not 
undergo any metabolic change and may persist in the body for a long period of time [204]. In 
addition, the autocatalytic property of CeO2 nanoparticles is thought to allow repeated cycling 
of Ce+4 to Ce+3 which may allow the particles to scavenge ROS indefinitely [118]. As such, 
studies investigating a second septic insult weeks after the initial one is resolved in the absence 
of subsequent treatments may be useful to better understand the true potential of using CeO2 
nanoparticles to treat sepsis.  
Specific Aim III: 
 Findings from the current study demonstrate that CeO2 nanoparticles protect male 
Sprague Dawley rats against severe sepsis when administered at the time of sepsis induction. 
However, most cases of deaths are seen in people that are admitted to the hospital at late or 
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final stages of sepsis where most of the irreparable damage has already been done. As such, 
studies investigating the therapeutic potential of CeO2 nanoparticles by post-administration of 
nanoceria several hours after sepsis induction may be warranted. 
 Finally, another major drawback to the current therapeutic regime aimed for the 
treatment of sepsis is the presence of comorbidity. Studies have shown that patients with 
preexisting conditions such as chronic renal failure or heart failure have a poorer prognosis 
following sepsis induction than those that do not [205]. As such, it may be of use to explore if 
post-administration of CeO2 nanoparticles can prevent sepsis induced MODS and mortality in 
individuals that have pre-existing diseases. 
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